

#### FOR IMMEDIATE RELEASE

### **HCP REPORTS THIRD QUARTER 2012 RESULTS**

#### RECENT HIGHLIGHTS

- -- FFO per share increased 6% to \$0.67; FFO as adjusted per share increased 3% to \$0.69; FAD per share increased 4% to \$0.55 and earnings per share increased 10% to \$0.45
- -- Year-over-year three- and nine-month cash NOI SPP increased 3.6% and 3.8%, respectively
- -- On October 16, 2012, announced a \$1.73 billion acquisition for a 133 senior housing portfolio and a \$52 million secured financing
- -- Completed an additional \$549 million of investment transactions:
  - \$205 million mezzanine loan facility
  - \$186 million acquisition of 12 on-campus MOBs from The Boyer Company in a DownREIT transaction
  - \$81 million acquisition of eight on-campus MOBs from Scottsdale Healthcare
  - \$77 million of other acquisitions and capital investments
- -- Expanded our tenant relationship with General Atomics in Poway, CA to a total of 396,000 sq. ft.
- -- Increased full-year 2012 FFO guidance to \$2.68 \$2.74 per share, FFO as adjusted guidance to \$2.75 \$2.81 per share and FAD guidance to \$2.20 \$2.26 per share
- -- Raised \$1.5 billion of capital:
  - £137 million (\$215 million) four-year 1.81% unsecured term loan
  - \$300 million ten-year 3.15% senior unsecured notes
  - \$979 million of common stock on October 19, 2012
- -- Named by the Global Real Estate Sustainability Benchmark survey as sector leader in the healthcare and hospitality category

LONG BEACH, CA, October 30, 2012 – HCP (the "Company" or "we") (NYSE:HCP) announced results for the quarter ended September 30, 2012 as follows (in thousands, except per share amounts):

		Three Months Ended September 30, 2012				Three Months Ended September 30, 2011				Per Share	
	Amount		Per Share		Amount		Per	Per Share		Change	
FFO Impairments	\$	290,242 7,878 <sup>(1)</sup>	\$	0.67 0.02	\$	259,571 15,400 <sup>(2)</sup>	\$	0.63 0.04	\$	0.04 (0.02)	
FFO as adjusted	\$	298,120	\$	0.69	\$	274,971	\$	0.67	\$	0.02	
FAD	\$	236,279	\$	0.55	\$	216,325	\$	0.53	\$	0.02	
Net income applicable to common shares	\$	195,629	\$	0.45	\$	166,367	\$	0.41	\$	0.04	

<sup>(1)</sup> The impairment charge during the three months ended September 30, 2012 relates to the pending sale of a land parcel in our life science segment.

FFO, FFO as adjusted and FAD are supplemental non-GAAP financial measures that the Company believes are useful in evaluating the operating performance of real estate investment trusts. See the "Funds From Operations" section of this release for additional information regarding FFO and FFO as adjusted and the "Funds Available for Distribution" section of this release for additional information regarding FAD.

<sup>(2)</sup> The impairment charge during the three months ended September 30, 2011 relates to our senior secured loan to Cirrus Health.

# ANNOUNCED \$1.73 BILLION SENIOR HOUSING PORTFOLIO ACQUISITION AND \$52 MILLION SECURED FINANCING

On October 16, 2012, we entered into a definitive agreement to acquire 133 senior housing communities for \$1.73 billion, from a joint venture between Emeritus Corporation ("Emeritus") and Blackstone Real Estate Partners VI, an affiliate of Blackstone (the "Blackstone JV"). Located in 29 states, the portfolio encompasses 10,350 units representing a diversified care mix of 61% assisted living, 25% independent living, 13% memory care and 1% skilled nursing. Based on current operating performance, the 133 communities consist of 99 that are stabilized and 34 currently in lease—up.

Emeritus and its affiliates will continue to operate the communities pursuant to long-term triple-net leases, all of which are guaranteed by the credit of Emeritus. The leases provide total contractual rent in the first year of \$105.5 million, representing a 6.1% lease yield. The contractual rent will increase annually by the greater of 3.7% on average or CPI over the initial five years, and thereafter by the greater of 3.0% or CPI for the remaining initial term. At the beginning of the sixth lease year, rent on the 34 lease—up properties will be increased to the greater of the percentage increase in CPI or fair market, subject to a floor of 103% and a cap of 130% of the prior year's rent, allowing HCP to capture potential upside from these non–stabilized assets. Under the leases, Emeritus is also required to invest an additional \$30 million in the portfolio, representing \$2,900 per unit.

The properties will be grouped into three comparable pools with initial terms of 14 to 16 years. Emeritus has two extension options, which, if exercised, bring total available lease terms to 30 to 35 years.

Concurrent with the acquisition, Emeritus will purchase nine communities from the Blackstone JV, for which we have agreed to provide secured debt financing of \$52 million with a four-year term. The loan is secured by the underlying real estate and is prepayable at Emeritus' option. The interest rate on the loan will mirror the 6.1% lease yield, including the annual increases through maturity.

We expect to close the real estate acquisition in phases beginning early November 2012.

#### ADDITIONAL INVESTMENT TRANSACTIONS

On July 31, 2012, we closed a mezzanine loan facility to lend up to \$205 million to Tandem Health Care ("Tandem"), an affiliate of Formation Capital, as part of the recapitalization of a post-acute/skilled nursing portfolio. We funded \$100 million (the "First Tranche") at closing and expect to fund an additional \$105 million (the "Second Tranche") between March 2013 and August 2013. The Second Tranche will be used to repay debt senior to our loan. The loan is subordinate to \$400 million in senior mortgage debt and \$137 million in senior mezzanine debt. The loan bears interest at a fixed rate of 12% and 14% per annum for the First and Second Tranche, respectively. Including fees received at closing, the loan has a blended yield to maturity of approximately 13%. The facility will have a total term of up to 63 months from the initial closing.

Between July and October 2012, we acquired 12 medical office buildings ("MOBs") from The Boyer Company valued at \$186 million, including non-managing member LLC units ("DownREIT units") and debt valued at \$41 million and \$59 million, respectively; the MOBs are primarily located on the campuses of HCA, lasis Healthcare and Community Health Systems and comprise 758,000 sq. ft. with a current occupancy of 88%. The transaction closed in three stages: (i) six MOBs on July 31, 2012 for \$78 million representing 327,000 sq. ft.; (ii) four MOBs on August 15, 2012 for \$49 million representing 199,000 sq. ft. and; (iii) two MOBs on October 19, 2012 for \$59 million representing 232,000 sq. ft.

On August 7, 2012, we completed the acquisition of eight on-campus MOBs for \$81 million from Scottsdale Healthcare. Located in Scottsdale, Arizona, the portfolio represents 398,000 sq. ft. with a current occupancy of 89%.

During the third quarter, we expanded our relationship with General Atomics in Poway, CA to a total of 396,000 sq. ft., consisting of the following: (i) a lease extension of 281,000 sq. ft. through June 2024, and (ii) a new 10–year lease (expected to commence mid–2014) for a 115,000 sq. ft. build—to—suit development. As part of this transaction, General Atomics agreed to purchase a 19–acre land parcel from HCP for \$19 million, resulting in a \$7.9 million non-cash impairment charge. This transaction monetizes and places into development 26 acres of land and represents a further reduction to our non-stabilized assets.

During the quarter, we made additional investments of \$77 million as follows: (i) acquisition of a MOB for \$14 million and (ii) funding of development and other capital projects of \$63 million, primarily in our life science, medical office and senior housing segments.

#### FINANCING ACTIVITIES

On July 23, 2012, we issued \$300 million of 3.15% senior unsecured notes due in 2022. The notes were priced at 98.888% of the principal amount with an effective yield-to-maturity of 3.28%. Net proceeds from this offering were \$293.7 million.

On July 30, 2012, we entered into a credit agreement with a syndicate of banks for a £137 million (\$215 million) four-year unsecured term loan that accrues interest at a rate of GBP LIBOR plus 1.20%. At closing, we entered into a four-year interest rate swap agreement that fixes the rate at 1.81%, subject to adjustments based on our credit ratings.

On October 19, 2012, we completed a public offering of 22 million shares of common stock and received net proceeds of \$979 million.

#### **SUSTAINABILITY**

During the quarter we (i) were named by the Global Real Estate Sustainability Benchmark survey as sector leader in the category that includes healthcare and hospitality; (ii) received a favorable score on our inaugural Carbon Disclosure Project Investor questionnaire; and (iii) earned two additional ENERGY STAR awards in our medical office segment. As of September 30, 2012, our medical office, life science and senior housing segments have been awarded 77 ENERGY STAR labels. More information about HCP's sustainability efforts can be found on our website at www.hcpi.com.

#### **DIVIDEND**

On October 25, 2012, we announced that our Board of Directors declared a quarterly cash dividend of \$0.50 per common share. The dividend will be paid on November 20, 2012 to stockholders of record as of the close of business on November 5, 2012.

#### OUTLOOK

For the full year 2012, we expect FFO applicable to common shares to range between \$2.68 and \$2.74 per share; FFO as adjusted applicable to common shares to range between \$2.75 and \$2.81 per share; FAD applicable to common shares to range between \$2.20 and \$2.26 per share; net income applicable to common shares to range between \$1.79 and \$1.85 per share; and cash same property performance growth to range from 4.0% to 4.5%.

Estimates of FFO and net income to common shares include the impact of our pending Senior Housing Portfolio Acquisition that is expected to close in phases beginning early November 2012, and the corresponding merger-related items. FFO as adjusted and FAD applicable to common shares exclude, among others items, the impact of merger-related items, which include direct transaction costs and negative carrying costs related to prefunding the Senior Housing Portfolio Acquisition. See the "Projected Future Operations" section of this release for additional information regarding these estimates.

#### **COMPANY INFORMATION**

HCP has scheduled a conference call and webcast for Tuesday, October 30, 2012 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) in order to present the Company's performance and operating results for the quarter ended September 30, 2012. The conference call is accessible by dialing (877) 724-7556 (U.S.) or (706) 645-4695 (International). The participant passcode is 35012696. The webcast is accessible via the Company's website at <a href="https://www.hcpi.com">www.hcpi.com</a>. This link can be found on the "Event Calendar" page, which is under the "Investor Relations" tab. Through November 13, 2012, an archive of the webcast will be available on our website and a telephonic replay can be accessed by calling (855) 859-2056 (U.S.) or (404) 537-3406 (International) and entering passcode 35012696. The Company's supplemental information package for the current period will also be available on the Company's website in the "Presentations" section of the "Investor Relations" tab.

#### **ABOUT HCP**

HCP, Inc. is a fully integrated real estate investment trust (REIT) that invests primarily in real estate serving the healthcare industry in the United States. The Company's portfolio of assets is diversified among five distinct sectors: senior housing, post-acute/skilled nursing, life science, medical office and hospitals. A publicly traded company since 1985, HCP: (i) was the first healthcare REIT selected to the S&P 500 index; (ii) has increased

its dividend per share for 27 consecutive years; and (iii) is the only REIT included in the S&P 500 Dividend Aristocrats index. For more information regarding HCP, visit the Company's website at <a href="https://www.hcpi.com">www.hcpi.com</a>.

###

#### FORWARD-LOOKING STATEMENTS

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this release which are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include among other things, net income applicable to common shares on a diluted basis, FFO applicable to common shares on a diluted basis, FFO as adjusted applicable to common shares on a diluted basis and FAD applicable to common shares on a diluted basis for the full year of 2012. These statements are made as of the date hereof, are not guarantees of future performance and are subject to known and unknown risks, uncertainties, assumptions and other factors—many of which are out of the Company and its management's control and difficult to forecast—that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to: the Company's ability to complete the senior housing portfolio acquisition and the secured loan described above on the currently proposed terms or at all; national and local economic conditions; continued volatility in the capital markets, including changes in interest rates and the availability and cost of capital, which changes and volatility affect opportunities for profitable investments; the Company's ability to access external sources of capital when desired and on reasonable terms; the Company's ability to manage its indebtedness levels; changes in the terms of the Company's indebtedness; the Company's ability to maintain its credit ratings; the potential impact of existing and future litigation matters, including the possibility of larger than expected litigation costs and related developments; the Company's ability to successfully integrate the operations of acquired companies; risks associated with the Company's investments in joint ventures and unconsolidated entities, including its lack of sole decision-making authority and its reliance on its joint venture partners' financial condition and continued cooperation; competition for lessees and mortgagors (including new leases and mortgages and the renewal or rollover of existing leases); the Company's ability to reposition its properties on the same or better terms if existing leases are not renewed or the Company exercises its right to replace an existing operator or tenant upon default; continuing reimbursement uncertainty in the post-acute/skilled nursing segment; competition in the senior housing segment specifically and in the healthcare industry in general; the ability of the Company's operators and tenants from its senior housing segment to maintain or increase their occupancy levels and revenues; the ability of the Company's lessees and mortgagors to maintain the financial strength and liquidity necessary to satisfy their respective obligations to the Company and other third parties; the bankruptcy, insolvency or financial deterioration of the Company's operators, lessees, borrowers or other obligors; changes in healthcare laws and regulations, including the impact of future or pending healthcare reform, and other changes in the healthcare industry which affect the operations of the Company's lessees or obligors, including changes in the federal budget resulting in the reduction or nonpayment of Medicare or Medicaid reimbursement rates; the Company's ability to recruit and retain key management personnel; costs of compliance with regulations and environmental laws affecting the Company's properties; changes in tax laws and regulations; changes in the financial position or business strategies of HCR ManorCare; the Company's ability and willingness to maintain its qualification as a REIT due to economic, market, legal, tax or other considerations; changes in rules governing financial reporting, including new accounting pronouncements; and other risks described from time to time in the Company's Securities and Exchange Commission filings. The Company assumes no, and hereby disclaims any, obligation to update any of the foregoing or any other forward-looking statements as a result of new information or new or future developments, except as otherwise required by law.

#### **CONTACT**

Timothy M. Schoen Executive Vice President and Chief Financial Officer 562-733-5309

# **Consolidated Balance Sheets**

# In thousands, except share and per share data (Unaudited)

	Se	eptember 30, 2012	December 31, 2011		
Assets					
Real estate:					
Buildings and improvements	\$	9,069,420	\$	8,822,653	
Development costs and construction in progress		229,543		190,590	
Land		1,724,563		1,723,601	
Accumulated depreciation and amortization		(1,662,116)		(1,452,688)	
Net real estate		9,361,410		9,284,156	
Net investment in direct financing leases		6,843,249		6,727,777	
Loans receivable, net		240,929		110,253	
Investments in and advances to unconsolidated joint ventures		217,092		224,052	
Accounts receivable, net of allowance of \$1,498 and \$1,341, respectively		31,763		26,681	
Cash and cash equivalents		96,476		33,506	
Restricted cash		43,428		41,553	
Intangible assets, net		382,321		372,390	
Real estate and intangible assets held for sale, net		91,226		102,649	
Other assets, net		771,442		485,458	
Total assets	\$	18,079,336	\$	17,408,475	
Liabilities and equity					
Bank line of credit	\$	_	\$	454,000	
Term loan		221,214		_	
Senior unsecured notes		5,913,690		5,416,063	
Mortgage debt		1,684,514		1,715,039	
Mortgage debt and intangible liabilities on assets held for sale, net		5,649		55,897	
Other debt		84,580		87,985	
Intangible liabilities, net		105,191		117,777	
Accounts payable and accrued liabilities		270,843		275,478	
Deferred revenues		65,802		65,614	
Total liabilities		8,351,483		8,187,853	
Preferred stock, \$1.00 par value: aggregate liquidation preference of \$295.5 million as of December 31,					
2011		_		285,173	
Common stock, \$1.00 par value: 750,000,000 shares authorized; 429,980,165 and 408,629,444 shares				203,173	
issued and outstanding, respectively		429,980		408,629	
Additional paid-in capital		10,185,982		9,383,536	
Cumulative dividends in excess of earnings		(1,081,317)		(1,024,274)	
Accumulated other comprehensive loss		(16,646)		(19,582)	
Total stockholders' equity		9,517,999		9,033,482	
Joint venture partners		14,884		16,971	
Non-managing member unitholders		194,970		170,169	
Total noncontrolling interests		209,854		187,140	
Total equity		9,727,853		9,220,622	
Total liabilities and equity	\$	18,079,336	\$	17,408,475	

# HCP, Inc. Consolidated Statements of Income

# In thousands, except per share data (Unaudited)

		Three Months Ended September 30,				Nine Months Ended September 30,			
		2012		2011		2012		2011	
Revenues:									
Rental and related revenues	\$	249,409	\$	250,809	\$	736,645	\$	758,322	
Tenant recoveries		23,425		23,879		69,656		69,764	
Resident fees and services		36,076		11,974		107,824		15,314	
Income from direct financing leases		155,834		153,496		465,345		310,553	
Interest income		10,278		577		12,313		99,199	
Investment management fee income		460		494		1,423		1,605	
Total revenues		475,482		441,229		1,393,206		1,254,757	
Costs and expenses:									
Interest expense		103,513		103,459		309,875		315,695	
Depreciation and amortization		88,686		86,672		259,039		265,742	
Operating		72,667		57,662		210,083		151,103	
General and administrative		19,443		19,647		54,356		76,471	
Impairments		7,878		15,400		7,878		15,400	
Total costs and expenses		292,187		282,840		841,231		824,411	
Other income (expense), net		770		(772)		2,233		17,056	
Income before income taxes and equity income from unconsolidated	1								
joint ventures	•	184,065		157,617		554,208		447,402	
Income taxes		598		(5)		1,131		(289)	
Equity income from unconsolidated joint ventures		13,396		17,050		42,803		32,798	
Income from continuing operations		198,059		174,662		598,142		479,911	
Discontinued operations:		<u> </u>		<del></del>		<u> </u>		<u> </u>	
Income (loss) before gain on sales of real estate, net of income taxes		984		809		(416)		3,796	
Gain on sales of real estate, net of income taxes		704		-		2,856		5,770	
Total discontinued operations		984		809		2,440		3,796	
Total discontinued operations		_	-		_	2,110	_		
Net income		199,043		175,471		600,582		483,707	
Noncontrolling interests' share in earnings		(2,935)		(3,276)		(9,070)		(12,660)	
Net income attributable to HCP, Inc.		196,108		172,195		591,512		471,047	
Preferred stock dividends				(5,282)		(17,006)		(15,848)	
Participating securities' share in earnings		(479)		(546)		(2,154)		(1,893)	
Net income applicable to common shares	\$	195,629	\$	166,367	\$	572,352	\$	453,306	
Basic earnings per common share:									
Continuing operations	\$	0.45	\$	0.41	\$	1.36	\$	1.14	
Discontinued operations		0.01		_		_		0.01	
Net income applicable to common shares	\$	0.46	\$	0.41	\$	1.36	\$	1.15	
Diluted earnings per common share:									
Continuing operations	\$	0.45	\$	0.41	\$	1.36	\$	1.13	
Discontinued operations	Ψ	0.10 —	Ψ	- O.11	Ψ	-	Ψ	0.01	
Net income applicable to common shares	\$	0.45	\$	0.41	\$	1.36	\$	1.14	
	Ψ	0.10	Ψ	0.11	Ψ	1.55	Ψ	1.11	
Weighted average shares used to calculate earnings per common									
share: Basic		420 EE7		407 001		420,049		30E 3E0	
		429,557		407,081			_	395,258	
Diluted		430,778		408,646		421,404		397,013	

# **Consolidated Statements of Cash Flows**

# In thousands (Unaudited)

Nine Months Ended

Cash flows from operating activities:         7012         7011           Retinations:         \$ 600,582         \$ 483,707           Adjustments for reconcile net income to net cash provided by operating activities:         5 500,582         \$ 685,742           Discontinuing operations:         255,913         255,742           Discontinuing operations:         7,200         4,266           Discontinuing operations:         7,200         4,266           Amentization of above and below market lease intenglibles, net         1,245         1,512           Amentization of deferred financing costs, net         1,241         1,518           Amentization of deferred financing costs, net         1,241         1,518           Amentization of deferred financing costs, net         1,411         1,518           Amentization of deferred financing costs, net         1,412         1,518           Amentization of cost financing lease interest accretion         1,410         1,528           Leglish promote in unucroscilidated pint ventures         2,755         2,426           Gain on sonsido of cost promote in unucroscilidated pint ventures         2,755         2,426           Gain upon consolidated pint ventures         2,755         2,242           Gain upon consolidated pint venture         1,526         2,281		Nine Months Ended September 30,						
Net   Income   \$0.05.02   \$4.83.707   Adjustments to reconcile net income to net cash provided by operating activities:   Depreciation and amoritation of real estate, in place lease and other intangibles:   259.039   265,742   Discontinued operations   7.300   4.266				inei 30				
Adjustments for econcile net income to net cash provided by operating activities:   Despired tabin and amortization of rael estate, in-place lease and other intangibles:   Descinting operations   7,300   4,286     Amortization of above and below market lease intangibles, net   1,855   3,271     Amortization of deferred formspensation   16,947   15,287     Amortization of deferred financing costs, net   12,415   3,271     Amortization of deferred financing costs, net   12,415   3,271     Amortization of deferred financing costs, net   10,110   16,8973     Loan and direct financing lease interest accretion   11,110   16,8973     Loan and direct financing lease interest accretion   11,110   16,8973     Deferred retail revenues   1,110   1,284     Equity income from unconsolidated joint ventures   2,856   3,276     Cath on sales of real estate   2,856   3,276     Cath upon consolidation of joint ventures   3,276   3,276     Cath upon consolidation of joint venture   3,276   3,276     Cath upon consolidation of joint venture   3,276   3,276     Cath upon consolidation of joint venture   3,276   3,276     Cath upon consolidation of joint ventures   3,276   3,276     Cath lows from investing activities   3,276   3,276     Cath lows from investing activities   3,276   3,276     Cath lows from investing activities   3,276   3,277     Cath lows from investing activities   3,277   3,270     Cath lows from invest	Cash flows from operating activities:				_			
Continuing operations		\$	600,582	\$	483,707			
Continuing operations         259,039         265,742           Discontinuing operations         1,300         4,266           Amonization of above and below market lease intangibles, net         (1,855)         (3,271)           Amonization of deferred compensation         16,647         15,268           Amonization of deferred compensation         (12,415)         22,118           Straight-line rems         (33,608)         (46,936)           Loan and dired triancing lase interest accretion         (71,923)         (65,973)           Deferred rental revenues         (1,101)         (1,248)           Equily income from unconsolidated joint ventures         (2,265)         -7.2           Calin on saiso of real estate         (2,856)         -7.2           Gain upon consolidation of joint ventures         (3,682)         -7.0           Gain upon consolidation of joint ventures         (3,682)         -7.0           Gain upon settlement of loans receivable         -8.4         (1,260)           Changes in:         -8.4         (1,260)           Accounts receivable, net         (5,082)         3.20           Other assets         (7,303)         28,631           Net cash provided by operating activities         (72,953)         586,921           Cash inous fr								
Discontinued operations			050 000		0/5 740			
Amonitzation of above and below market lease intangibles, net         16,947         15,286           Amonitzation of deferred compensation         16,947         15,286           Amonitzation of deferred financing costs, net         12,415         22,118           Straigh-like reits         (33,08)         (46,936)           Loan and direct financing losse interest accretion         (71,923)         (65,973)           Deferred rental revenues         (2,856)         -7.75           Egulty income from unconsolidated joint ventures         (2,856)         -7.22           Cain on sales or real estate         (2,856)         -7.22           Cain upon consolidation of joint ventures         (2,769)         (2,277,50)           Cain upon consolidation of joint ventures         (3,682)         (7,769)           Gain upon screekable         -4         (22,818)           Derivative (gains) losses, net         (3         (1,226)           Impairments         (3,682)         3,206           Changes in:         (3,730)         28,631           Accounts receivable, net         (5,082)         3,206           Other assets         (3,730)         28,631           Accounts receivable, net         (3,730)         28,631           Obler assets provided by operating activi								
Annotization of delered compensation         16,947         15,286           Annotization of delered financing costs, net         12,415         22,118           Straight-line rents         (33,608)         (44,932)           Loan and direct financing lease interest accretion         (71,923)         (65,973)           Deferred rental revenues         (1,101)         (1,284)           Equity income from unconsolidated joint ventures         (2,806)         7,769           Gain on sales of real estate         (2,866)         7,769           Gain upon settlement of loans receivable         -         (7,769)           Gain upon settlement of loans receivable         -         (7,878)           Derivative (gains) losses, net         43         (1,226)           Impairments         (5,082)         3,206           Changes in         (7,303)         28,631           Accounts receivable, net         (5,082)         3,206           Other assets         (7,303)         28,631           Accounts payable and accrued liabilities         (7,303)         28,631           Recarb provided by operating activities         (21,697)         (71,848)           Cash used in the HCR ManorCare Acquisition, net of cash acquired         -         (8,006)           Cash used in the								
Annotization of deferred financing costs, net         12,415         22,118           Straight-line ronts         (33,608)         (46,936)           Loan and direct financing lease interest accretion         (71,923)         (65,973)           Deliered rental revenues         1,101         (1,284)           Equily income from unconsolidated joint ventures         2,775         2,622           Clain on sales of real estate         2,856         —           Calin upon consolidation of joint venture         —         (7,769)           Gain upon sottlement of foat six receivable         —         43         (1,226)           Derivative (gains) losses, net         43         (1,226)         —           Accounts spayable and accrued liabilities         7,878         15,400           Changes in:         Accounts payable and accrued liabilities         70,303         2,861           Accounts payable and accrued liabilities         720,953         558,921           Cash used in the HCR Mannocrae Acquisition, net of cash acquired         —         (10,65,56)           Cash used in the HCR Mannocrae Acquisition, net of cash acquired         —         (135,550)           Cash used in the HCR Mannocrae Acquisition, set of cash acquired         —         (5,062)           Cash used in the HCR Mannocrae Acquisition, set of cash								
Straight-line rents         (33,608)         (46,936)           Loan and direct financing lease interest accretion         (71,723)         (65,973)           Deferred rental revenues         1,101         (1,848)           Equity income from unconsolidated joint ventures         (2,856)								
Deferred reneal recentage   1,101								
Deferred rental revenues         1.101         (1.24)           Equily income from unconsolidated joint ventures         (2.283)         (32.778)           Distributions of earnings from unconsolidated joint ventures         2.775         2.462           Gain upon settlement of loans receivable         —         (2.2812)           Derivative (glans) losses, net         43         (1.226)           Derivative (glans) losses, net         43         (1.202)           Impairments         7.878         15.400           Changes in:         (5.082)         3.206           Other assetts         (7.303)         28.631           Accounts receivable, net         (5.082)         3.206           Other assets         (7.1083)         58.6921           Cash other from investing activities         72.0953         586.921           Cash lows from investing activities         72.0953         586.921           Cash used in the HCR ManorCare Acquisition, net of cash acquired         —         (4.026, 556)           Cash used in the HCR ManorCare Acquisition, net of cash acquired         —         (3.5550)           Cheir acquisitions of real estate         (87.119)         (57.167)           Leasing costs and tenant and capital improvements         (2.826)         (2.877)								
Capity income from unconsolidated joint ventures								
Distributions of earnings from unconsolidated joint ventures         2,775         2,462           Gain upon consolidation of joint venture         — (7,769)           Gain upon settlement of loans receivable         — (2,2182)           Derrabative (gains) losses, net         43         (1,226)           Impairments         7,878         15,400           Changes in:         — (5,082)         3,206           Changes in:         (5,082)         3,206           Other assets         (73,03)         28,631           Accounts payable and accrued liabilities         (21,697)         (71,848)           Accounts payable and accrued liabilities         (21,697)         (71,848)           Accounts provided by operating activities:         — (20,000)         28,6921           Cash flows from investing activities:         — (10,000)         10,000         28,9921           Cash flows from investing activities:         — (10,000)         10,000         113,462         113,462           Other acquisitions of real estate         (17,238)         — (10,000)         113,462         113,462           Other acquisitions of real estate         (17,238)         — (20,000)         113,462         113,462         113,462         113,462         113,462         113,462         113,462								
Gain on sales of real estate         (2,856)         —           Gain upon consolidation of joint venture         —         (2,2812)           Cain upon settlement of loans receivable         —         (22,812)           Dervative (gains) losses, net         43         (1,246)           Impairments         7,878         15,400           Changes in:         —         -           Accounts receivable, net         (5,082)         3,206           Other assets         (7,303)         28,631           Accounts payable and accrued liabilities         (70,303)         28,631           Net eash provided by operating activities         720,953         586,921           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (4,026,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (135,550)           Other acquisitions of real estate         (87,119)         (57,167)           Leasing costs and tenant and capital improvements         (87,119)         (57,167)           Leasing costs and tenant and capital improvements         2,2051         1,738           Purchase of an interest in unconsolidated joint ventures         —         (95,000)           Distributions in excess of earnings from unconsolidated joint ventures         (20								
Gain upon consolidation of joint venture         —         (7.769)           Gain upon settlement of loans receivable         —         (22.8112)           Derivative (gains) losses, net         43         (1.226)           Impairments         7,878         15,400           Changes in:         —         —           Accounts receivable, net         (5.082)         3,206           Other assets         (21.697)         (71.848)           Accounts payable and accrued liabilities         (21.697)         (71.848)           Acto on the provided by operating activities         21.697)         (71.848)           Cash flows from investing activities         —         (4.026,556)           Cash used in the HCR ManorCare Acquisition, net of cash acquired         —         (4.026,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (4.026,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (4.026,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (4.026,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (4.026,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (4.026,556)           Cash					2,102			
Gain upon settlement of loans receivable         -         (22.812)           Derivative (gains) losses, net         43         (1.226)           Impairments         7.878         15.400           Changes in:         6.082         3.206           Accounts receivable, net         (5.082)         3.206           Other assets         (7.303)         28.631           Accounts payable and accrued liabilities         (21.697)         (71.848)           Net cash provided by operating activities         720.953         586.921           Cash used in the HCR ManorCare Acquisition, net of cash acquired         -         (4026.556)           Cash used in the HCR Ventures II purchase, net of cash acquired         -         (135.550)           Other acquisitions of real estate         (87.119)         (57.167)           Leasing costs and tenant and capital improvements         (42.817)         (31.726)           Leasing costs and tenant and capital improvements         -         (95.000)           Distributions in excess of earnings from unconsolidated joint ventures         -         (95.000)           Distributions in excess of earnings from unconsolidated joint ventures         2.01         1,936           Purchase of marketable securities         4.600         303.867           Investments in loans receivab			(2/555)		(7.769)			
Drivative (gains) losses, net         43         (1,226)           Impairments         7,878         15,000           Changes in:			_					
Table   Tabl			43					
Changes In:         (5,082)         3,206           Accounts receivable, net         (5,082)         3,206           Other assets         (21,697)         (71,948)           Net cash provided by operating activities         720,953         586,921           Cash flows from investing activities:         ***         ***           Cash used in the HCR ManorCare Acquisition, net of cash acquired         —         (35,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (313,5550)           Cash used in the HCP ventures II purchase, net of cash acquired         —         (313,5550)           Cash used in the HCP ventures II purchase, net of cash acquired         —         (313,5550)           Oberelopment of real estate         (87,119)         (57,167)           Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         2,051         1,936           Purchase of an interest in unconsolidated joint ventures         2,051         1,936           Purchase of an interest in unconsolidated joint ventures         2,051         1,936           Purchase of an interest in unconsolidated joint ventures         2,051			7,878					
Other assels         (7.303)         28.631           Accounts payable and accrued liabilities         (21,697)         (71,848)           Net cash provided by operating activities:         720,953         586,921           Cash used in the HCR ManorCare Acquisition, net of cash acquired         — (40,26,556)           Cash used in the HCR Ventures II purchase, net of cash acquired         — (135,550)           Other acquisitions of real estate         (172,380)         (113,462)           Development of real estate         (87,119)         (57,167)           Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (21,859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (1,855)         (1,855)           Net cash used in investing activities         (50,698)         (4,551,022)           Robrowings (repayments on loans receivable         (1,855)         (1,855)           Net case in restricted cash         (1,855)         (1,855)           Net cash used in investing activiti								
Accounts payable and accrued liabilities         (71,848)           Net cash provided by operating activities         720,953         586,921           Cash flows from investing activities         720,953         586,921           Cash used in the HCR ManorCare Acquisition, net of cash acquired         —         (4,026,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (135,550)           Other acquisitions of real estate         (87,119)         (57,167)           Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (21,4859)         (22,449)           Purchase of marketable securities         (21,4859)         (22,449)           Purchase of marketable securities         (145,597)         (36,337)           Increase in restricted cash         (18,75)         (11,532)           Net cash used in investing activities         (500,698)         (4,551,022)           Ret borrowings (repayments) under bank line of credit         (50,009)         (4,551,022)           Net cash used in investing activities         (50,009)         (4,551,022)	Accounts receivable, net		(5,082)		3,206			
Net cash provided by operating activities:         720,953         586,921           Cash flows from investing activities:         Cash used in the HCR ManorCare Acquisition, net of cash acquired         —         (135,550)           Cash used in the HCR Ventures II purchase, net of cash acquired         —         (135,550)           Other acquisitions of real estate         (87,119)         (57,167)           Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         —         95,000           Distributions in excess of earnings from unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (214,859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         4,660         303,867           Investments in loans receivable         (18,597)         (363,337)           Increase in restricted cash         (18,597)         (363,337)           Increase in restricted cash         (18,597)         (363,337)           Retail used in investing activities         (50,698)         (4,551,022)           Retail uses from financing activi	Other assets				28,631			
Cash flows from investing activities:         (4,026,556)           Cash used in the HCR ManorCare Acquisition, net of cash acquired         —         (4,026,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         —         (135,550)           Other acquisitions of real estate         (172,380)         (113,462)           Development of real estate         (37,119)         (57,167)           Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (21,859)         (22,449)           Pincipal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (1,875)         (15,597)           Increase in restricted cash         (1,875)         (15,592)           Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortgage debt         (10,9569)         (15,2517)           Issuance of senior unsecured no	Accounts payable and accrued liabilities		(21,697)					
Cash used in the HCR ManorCare Acquisition, net of cash acquired         —         (4,026,556)           Cash used in the HCP Ventures II purchase, net of cash acquired         (172,380)         (113,550)           Other acquisitions of real estate         (87,119)         (57,167)           Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         —         (95,000)           Distributions in excess of earnings from unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (214,859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (1,875)         (11,532)           Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities         (650,698)         (4,551,022)           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortigage debt         (50,000)         (292,265)           Deferred financing costs         (50,000)	Net cash provided by operating activities		720,953		586,921			
Cash used in the HCP Ventures II purchase, net of cash acquired         — (135,550)           Other acquisitions of real estate         (172,380)         (113,462)           Development of real estate         (87,117)         (57,167)           Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         2,051         1,936           Purchase of an interest in unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (214,889)         (22,449)           Principal repayments on loans receivable         (45,000)         33,386           Investments in loans receivable         (145,597)         (363,337)           Increase in restricted cash         (1875)         (11,532)           Net cash used in investing activities         (850,698)         (4,551,022)           Cash flows from financing activities         (850,698)         (4,551,022)           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         (214,789)         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuanc								
Other acquisitions of real estate         (172,380)         (113,462)           Development of real estate         (87,119)         (57,167)           Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         —         (95,000)           Distributions in excess of earnings from unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (214,859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (145,597)         (363,337)           Increase in restricted cash         (18,75)         (1,1532)           Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities         (650,698)         (4,551,022)           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings (repayments) under bank line of credit         (50,000)			_					
Development of real estate         (87,119)         (57,167)           Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         —         (95,000)           Distributions in excess of earnings from unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (214,859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (145,597)         (363,337)           Increase in restricted cash         (1,875)         (11,532)           Net cash used in investing activities         (56,0698)         (4,551,022)           Cash flows from financing activities         (56,0698)         (4,551,022)           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (58,048)         (40,000)           Repayment of			_					
Leasing costs and tenant and capital improvements         (42,817)         (31,772)           Proceeds from sales of real estate, net         7,238         —         (95,000)           Distributions in excess of earnings from unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (214,859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (18,55)         (11,532)           Increase in restricted cash         (1,875)         (11,532)           Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities:         ***           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividend								
Proceeds from sales of real estate, net         7,238         —           Purchase of an interest in unconsolidated joint ventures         —         (95,000)           Distributions in excess of earnings from unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (214,859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (1,875)         (13,532)           Increase in restricted cash         (50,698)         (4,551,022)           A to cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities         **         **           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         (250,000)         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common sto								
Purchase of an interest in unconsolidated joint ventures         —         (95,000)           Distributions in excess of earnings from unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (214,859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (145,597)         (363,337)           Increase in restricted cash         (1,875)         (11,532)           Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities:					(31,772)			
Distributions in excess of earnings from unconsolidated joint ventures         2,051         1,936           Purchase of marketable securities         (214,859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (185,597)         (363,337)           Increase in restricted cash         (1,875)         (11,532)           Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities:         (650,698)         (4,551,022)           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         750,000         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividends paid on common and preferred stock         (638,228)         (586,048)	·		7,238		(05.000)			
Purchase of marketable securities         (21,4859)         (22,449)           Principal repayments on loans receivable         4,660         303,867           Investments in loans receivable         (145,597)         (363,337)           Increase in restricted cash         (1,875)         (11,532)           Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities         ***         ***           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789            Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         750,000         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         -           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividends paid on common and preferred stock         (638,228)         (586,048)           Issuance of noncontrolling interests         826         14,028           Purchase of noncontrolling interests </td <td></td> <td></td> <td>2.051</td> <td></td> <td></td>			2.051					
Principal repayments on loans receivable Investments in loans receivable Investments In								
Investments in loans receivable         (145,597)         (363,337)           Increase in restricted cash         (1,875)         (11,532)           Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities:         ***           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         750,000         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividends paid on common and preferred stock         (638,228)         (586,048)           Issuance of noncontrolling interests         826         14,028           Purchase of noncontrolling interests         826         14,028           Purchase of noncontrolling interests         (11,759)         (11,001)           Net cash provided by (used in) financing activities <th< td=""><td></td><td></td><td></td><td></td><td></td></th<>								
Increase in restricted cash         (1,875)         (11,532)           Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities:           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         750,000         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividends paid on common and preferred stock         (638,228)         (586,048)           Issuance of noncontrolling interests         826         14,028           Purchase of noncontrolling interests         —         (34,104)           Distributions to noncontrolling interests         (11,759)         (11,001)           Net cash provided by (used in) financing activities         (7,285)         2,972,260           Net increase (decrease) in cash and cash equivalents </td <td></td> <td></td> <td></td> <td></td> <td></td>								
Net cash used in investing activities         (650,698)         (4,551,022)           Cash flows from financing activities:         (454,000)         375,000           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         750,000         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividends paid on common and preferred stock         (638,228)         (586,048)           Issuance of noncontrolling interests         826         14,028           Purchase of noncontrolling interests         —         (34,104)           Distributions to noncontrolling interests         (11,759)         (11,001)           Net cash provided by (used in) financing activities         (7,285)         2,972,260           Net increase (decrease) in cash and cash equivalents         62,970         (991,841)								
Cash flows from financing activities:           Net borrowings (repayments) under bank line of credit         (454,000)         375,000           Borrowings under term loan         214,789         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         750,000         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividends paid on common and preferred stock         (638,228)         (586,048)           Issuance of noncontrolling interests         826         14,028           Purchase of noncontrolling interests         —         (34,104)           Distributions to noncontrolling interests         —         (34,104)           Net increase (decrease) in cash and cash equivalents         62,970         (991,841)           Cash and cash equivalents, beginning of period         33,506         1,036,701								
Net borrowings (repayments) under bank line of credit       (454,000)       375,000         Borrowings under term loan       214,789       —         Repayments of mortgage debt       (109,569)       (152,517)         Issuance of senior unsecured notes       750,000       2,400,000         Repayment of senior unsecured notes       (250,000)       (292,265)         Deferred financing costs       (18,256)       (43,716)         Preferred stock redemption       (295,500)       —         Net proceeds from the issuance of common stock and exercise of options       804,412       1,302,883         Dividends paid on common and preferred stock       (638,228)       (586,048)         Issuance of noncontrolling interests       826       14,028         Purchase of noncontrolling interests       —       (34,104)         Distributions to noncontrolling interests       (11,759)       (11,001)         Net cash provided by (used in) financing activities       (7,285)       2,972,260         Net increase (decrease) in cash and cash equivalents       62,970       (991,841)         Cash and cash equivalents, beginning of period       33,506       1,036,701			(030,070)		(4,331,022)			
Borrowings under term loan         214,789         —           Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         750,000         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividends paid on common and preferred stock         (638,228)         (586,048)           Issuance of noncontrolling interests         826         14,028           Purchase of noncontrolling interests         —         (34,104)           Distributions to noncontrolling interests         (11,759)         (11,001)           Net cash provided by (used in) financing activities         (7,285)         2,972,260           Net increase (decrease) in cash and cash equivalents         62,970         (991,841)           Cash and cash equivalents, beginning of period         33,506         1,036,701			(454 000)		375 000			
Repayments of mortgage debt         (109,569)         (152,517)           Issuance of senior unsecured notes         750,000         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividends paid on common and preferred stock         (638,228)         (586,048)           Issuance of noncontrolling interests         826         14,028           Purchase of noncontrolling interests         —         (34,104)           Distributions to noncontrolling interests         (11,759)         (11,001)           Net cash provided by (used in) financing activities         (7,285)         2,972,260           Net increase (decrease) in cash and cash equivalents         62,970         (991,841)           Cash and cash equivalents, beginning of period         33,506         1,036,701			, , ,		575,000 —			
Issuance of senior unsecured notes         750,000         2,400,000           Repayment of senior unsecured notes         (250,000)         (292,265)           Deferred financing costs         (18,256)         (43,716)           Preferred stock redemption         (295,500)         —           Net proceeds from the issuance of common stock and exercise of options         804,412         1,302,883           Dividends paid on common and preferred stock         (638,228)         (586,048)           Issuance of noncontrolling interests         826         14,028           Purchase of noncontrolling interests         —         (34,104)           Distributions to noncontrolling interests         (11,759)         (11,001)           Net cash provided by (used in) financing activities         (7,285)         2,972,260           Net increase (decrease) in cash and cash equivalents         62,970         (991,841)           Cash and cash equivalents, beginning of period         33,506         1,036,701					(152.517)			
Repayment of senior unsecured notes(250,000)(292,265)Deferred financing costs(18,256)(43,716)Preferred stock redemption(295,500)—Net proceeds from the issuance of common stock and exercise of options804,4121,302,883Dividends paid on common and preferred stock(638,228)(586,048)Issuance of noncontrolling interests82614,028Purchase of noncontrolling interests—(34,104)Distributions to noncontrolling interests(11,759)(11,001)Net cash provided by (used in) financing activities(7,285)2,972,260Net increase (decrease) in cash and cash equivalents62,970(991,841)Cash and cash equivalents, beginning of period33,5061,036,701								
Deferred financing costs(18,256)(43,716)Preferred stock redemption(295,500)—Net proceeds from the issuance of common stock and exercise of options804,4121,302,883Dividends paid on common and preferred stock(638,228)(586,048)Issuance of noncontrolling interests82614,028Purchase of noncontrolling interests—(34,104)Distributions to noncontrolling interests(11,759)(11,001)Net cash provided by (used in) financing activities(7,285)2,972,260Net increase (decrease) in cash and cash equivalents62,970(991,841)Cash and cash equivalents, beginning of period33,5061,036,701								
Preferred stock redemption(295,500)—Net proceeds from the issuance of common stock and exercise of options804,4121,302,883Dividends paid on common and preferred stock(638,228)(586,048)Issuance of noncontrolling interests82614,028Purchase of noncontrolling interests—(34,104)Distributions to noncontrolling interests(11,759)(11,001)Net cash provided by (used in) financing activities(7,285)2,972,260Net increase (decrease) in cash and cash equivalents62,970(991,841)Cash and cash equivalents, beginning of period33,5061,036,701								
Net proceeds from the issuance of common stock and exercise of options804,4121,302,883Dividends paid on common and preferred stock(638,228)(586,048)Issuance of noncontrolling interests82614,028Purchase of noncontrolling interests—(34,104)Distributions to noncontrolling interests(11,759)(11,001)Net cash provided by (used in) financing activities(7,285)2,972,260Net increase (decrease) in cash and cash equivalents62,970(991,841)Cash and cash equivalents, beginning of period33,5061,036,701								
Dividends paid on common and preferred stock(638,228)(586,048)Issuance of noncontrolling interests82614,028Purchase of noncontrolling interests—(34,104)Distributions to noncontrolling interests(11,759)(11,001)Net cash provided by (used in) financing activities(7,285)2,972,260Net increase (decrease) in cash and cash equivalents62,970(991,841)Cash and cash equivalents, beginning of period33,5061,036,701					1,302,883			
Issuance of noncontrolling interests82614,028Purchase of noncontrolling interests—(34,104)Distributions to noncontrolling interests(11,759)(11,001)Net cash provided by (used in) financing activities(7,285)2,972,260Net increase (decrease) in cash and cash equivalents62,970(991,841)Cash and cash equivalents, beginning of period33,5061,036,701			(638,228)		(586,048)			
Distributions to noncontrolling interests(11,759)(11,001)Net cash provided by (used in) financing activities(7,285)2,972,260Net increase (decrease) in cash and cash equivalents62,970(991,841)Cash and cash equivalents, beginning of period33,5061,036,701	Issuance of noncontrolling interests		826		14,028			
Net cash provided by (used in) financing activities(7,285)2,972,260Net increase (decrease) in cash and cash equivalents62,970(991,841)Cash and cash equivalents, beginning of period33,5061,036,701			_					
Net increase (decrease) in cash and cash equivalents62,970(991,841)Cash and cash equivalents, beginning of period33,5061,036,701								
Cash and cash equivalents, beginning of period 33,506 1,036,701								
Cash and cash equivalents, end of period \$ 96,476 \$ 44,860								
	Cash and cash equivalents, end of period	\$	96,476	\$	44,860			

#### Funds From Operations(1)

# In thousands, except per share data (Unaudited)

		Three Mon Septem		 Nine Mont Septem	
		2012	2011	2012	2011
Net income applicable to common shares	\$	195,629	\$ 166,367	\$ 572,352	\$ 453,306
Depreciation and amortization of real estate, in-place lease and other intangibles:					
Continuing operations		88,686	86,672	259,039	265,742
Discontinued operations		1,453	1,884	7,300	4,286
Direct financing lease ("DFL") depreciation		3,234	2,874	9,426	5,879
Gain on sales of real estate		_	_	(2,856)	_
Gain upon consolidation of joint venture		_	_	_	(7,769)
Equity income from unconsolidated joint ventures		(13,396)	(17,050)	(42,803)	(32,798)
FFO from unconsolidated joint ventures		16,043	19,574	50,495	40,408
Noncontrolling interests' and participating securities' share in earnings	S	3,414	3,822	11,224	14,553
Noncontrolling interests' and participating securities' share in FFO		(4,821)	(4,572)	(15,512)	(16,385)
FFO applicable to common shares	\$	290,242	\$ 259,571	\$ 848,665	\$ 727,222
Distributions on dilutive convertible units		3,148	3,048	9,397	9,066
Diluted FFO applicable to common shares	\$	293,390	\$ 262,619	\$ 858,062	\$ 736,288
Diluted FFO per common share	\$	0.67	\$ 0.63	\$ 2.01	\$ 1.83
Weighted average shares used to calculate diluted FFO per share		437,043	414,590	427,388	402,967
Impact of adjustments to FFO:  Preferred stock redemption charge <sup>(2)</sup>		_		10,432	
Merger-related items <sup>(3)</sup>				10,432	26.596
Impairments <sup>(4)</sup>		7,878	15,400	7,878	15,400
impairments.	\$	7,878	\$ 15,400	\$ 18,310	\$ 41,996
FFO as adjusted applicable to common shares	\$	298,120	\$ 274,971	\$ 866,975	\$ 769,218
Distributions on dilutive convertible units and other		3,127	3,011	9,345	8,927
Diluted FFO as adjusted applicable to common shares	\$	301,247	\$ 277,982	\$ 876,320	\$ 778,145
Per common share impact of adjustments on diluted FFO	\$	0.02	\$ 0.04	\$ 0.04	\$ 0.19
Diluted FFO as adjusted per common share	\$	0.69	\$ 0.67	\$ 2.05	\$ 2.02
Weighted average shares used to calculate diluted FFO as adjusted per share		437,043	414,590	427,388	385,693

<sup>(1)</sup> We believe Funds From Operations ("FFO") is an important supplemental measure of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term FFO was designed by the REIT industry to address this issue. FFO is defined as net income applicable to common shares (computed in accordance with U.S. generally accepted accounting principles or "GAAP"), excluding gains or losses from acquisition and dispositions of depreciable real estate or related interests, impairments of, or related to, depreciable real estate, plus real estate and DFL depreciation and amortization, with adjustments for joint ventures. Adjustments for joint ventures are calculated to reflect FFO on the same basis. FFO does not represent cash generated from operating activities determined in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income. Our computation of FFO may not be comparable to FFO reported by other REITs that do not define the term in accordance with the current National Association of Real Estate Investment Trusts' ("NAREIT") definition or that have a different interpretation of the current NAREIT definition from us. In addition, we present FFO before the impact of litigation settlement charges, preferred stock redemption charges, impairments (recoveries) of non-depreciable assets and merger-related items ("FFO as adjusted"). Management believes FFO as adjusted is a useful alternative measurement. This measure is a modification of the NAREIT definition of FFO and should not be used as an alternative to net

<sup>(2)</sup> In connection with the redemption of our preferred stock, we incurred a one-time, non-cash redemption charge of \$10.4 million or \$0.02 per share related to the original issuance costs of the preferred stock.

<sup>(3) \$26.6</sup> million or \$0.15 per share of merger-related items attributable to the HCR ManorCare acquisition, which closed on April 7, 2011.

<sup>(4)</sup> The third quarter 2012 impairment charge of \$7.9 million, or \$0.02 per share, relates to the pending sale of a land parcel in our life science segment. The third quarter 2011 impairment charge of \$15.4 million, or \$0.04 per share, relates to our senior secured loan to Cirrus Health.

#### Funds Available for Distribution(1)

# In thousands, except per share data (Unaudited)

	Three Months Ended September 30,				Nine Months Ended September 30,			
		2012		2011		2012		2011
FFO as adjusted applicable to common shares  Amortization of above and below market lease intangibles, net	\$	298,120 (533)	\$	274,971 (1,178)	\$	866,975 (1,855)	\$	769,218 (3,271)
Amortization of deferred compensation  Amortization of deferred financing costs, net		5,540 3,956		5,081 3,716		16,947 12,415		15,286 10,065
Straight-line rents DFL accretion <sup>(2)</sup>		(11,821) (23,433)		(14,024) (23,571)		(33,608) (71,072)		(46,936) (48,508)
DFL depreciation Deferred revenues – tenant improvement related		(3,234) (424)		(2,874) (491)		(9,426) (1,257)		(5,879) (2,134)
Deferred revenues – additional rents (SAB 104) Leasing costs and tenant and capital improvements		356 (15,705)		284 (10,832)		2,358 (42,817)		850 (31,772)
Joint venture and other FAD adjustments <sup>(2)</sup> FAD applicable to common shares	\$	(16,543) 236,279	\$	(14,757) 216,325	\$	(43,219) 695,441	\$	(29,087) 627,832
Distributions on dilutive convertible units		1,827		1,756		5,404		5,158
Diluted FAD applicable to common shares	\$	238,106	\$	218,081	\$	700,845	\$	632,990
Diluted FAD per common share	\$	0.55	\$	0.53	\$	1.65	\$	1.65
Weighted average shares used to calculate diluted FAD per common share		434,786		412,305		425,121		383,397

<sup>(</sup>i) Funds Available for Distribution ("FAD") is defined as FFO as adjusted after excluding the impact of the following: (i) amortization of acquired above/below market lease intangibles, net; (ii) amortization of deferred compensation expense; (iii) amortization of deferred financing costs, net; (iv) straight-line rents; (v) accretion and depreciation related to DFLs; and (vi) deferred revenues. Further, FAD is computed after deducting recurring capital expenditures, including leasing costs and second generation tenant and capital improvements and includes similar adjustments to compute our share of FAD from our unconsolidated joint ventures. Other REITs or real estate companies may use different methodologies for calculating FAD, and accordingly, our FAD may not be comparable to those reported by other REITs. Although our FAD computation may not be comparable to that of other REITs, management believes FAD provides a meaningful supplemental measure of our ability to fund its ongoing dividend payments. In addition, management believes that in order to further understand and analyze our liquidity, FAD should be compared with net cash flows from operating activities as determined in accordance with GAAP and presented in its consolidated financial statements. FAD does not represent cash generated from operating activities determined in accordance with GAAP, and FAD should not be considered as an alternative to net income (determined in accordance with GAAP) as an indication of our performance, as an alternative to net cash flows from operating activities (determined in accordance with GAAP), or as a measure of our liquidity.

<sup>(2)</sup> For the three and nine months ended September 30, 2012, DFL accretion reflects an elimination of \$14.9 million and \$44.4 million, respectively. For the three and nine months ended September 30, 2011, DFL accretion reflects an elimination of \$14.4 million and \$27.7 million, respectively. Our ownership in HCR ManorCare OpCo is accounted for using the equity method, which requires an ongoing elimination of DFL income that is proportional to our ownership in HCR ManorCare OpCo. Further, our share of earnings from HCR ManorCare OpCo (equity income) increases for the corresponding elimination of related lease expense recognized at the HCR ManorCare OpCo level, which we present as a non-cash joint venture FAD adjustment.

#### Net Operating Income and Same Property Performance(1)(2)

# Dollars in thousands (Unaudited)

	 Three Mor Septem		 Nine Mont Septem		
	2012	2011	2012		2011
Net income	\$ 199,043	\$ 175,471	\$ 600,582	\$	483,707
Interest income	(10,278)	(577)	(12,313)		(99,199)
Investment management fee income	(460)	(494)	(1,423)		(1,605)
Interest expense	103,513	103,459	309,875		315,695
Depreciation and amortization	88,686	86,672	259,039		265,742
General and administrative	19,443	19,647	54,356		76,471
Impairments	7,878	15,400	7,878		15,400
Other income, net	(770)	772	(2,233)		(17,056)
Income taxes	(598)	5	(1,131)		289
Equity income from unconsolidated joint ventures	(13,396)	(17,050)	(42,803)		(32,798)
Total discontinued operations, net of income taxes	(984)	(809)	(2,440)		(3,796)
NOI <sup>(1)</sup>	\$ 392,077	\$ 382,496	\$ 1,169,387	\$	1,002,850
Straight-line rents	(11,821)	(14,024)	(33,608)		(46,936)
DFL accretion	(23,433)	(23,571)	(71,072)		(48,508)
Amortization of above and below market lease intangibles, net	(533)	(1,178)	(1,855)		(3,271)
Lease termination fees	(175)	(239)	(574)		(3,417)
NOI adjustments related to discontinued operations	335	516	1,437		1,585
Adjusted NOI(1)	\$ 356,450	\$ 344,000	\$ 1,063,715	\$	902,303
Non-SPP adjusted NOI	(12,215)	(11,799)	(405,713)		(268,649)
Same property portfolio adjusted NOI <sup>(2)</sup>	\$ 344,235	\$ 332,201	\$ 658,002	\$	633,654
Adjusted NOI % change – SPP(2)	 3.6%		3.8%		

<sup>(1)</sup> We believe Net Operating Income from Continuing Operations ("NOI") provides investors relevant and useful information because it reflects only income and operating expense items that are incurred at the property level and presents them on an unleveraged basis. We use NOI and adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and evaluate SPP. We believe that net income is the most directly comparable GAAP measure to NOI. NOI should not be viewed as an alternative measure of operating performance to net income (determined in accordance with GAAP) since it excludes certain components from net income. Further, NOI may not be comparable to that of other REITs, as they may use different methodologies for calculating NOI.

NOI is defined as rental and related revenues, including tenant recoveries, resident fees and services, and income from DFLs, less property level operating expenses. NOI excludes interest income, investment management fee income, interest expense, depreciation and amortization, general and administrative expenses, litigation settlement, impairments, impairment recoveries, other income, net, income taxes, equity income from and impairments of unconsolidated joint ventures, and discontinued operations. Adjusted NOI is calculated as NOI eliminating the effects of straight-line rents, DFL accretion, amortization of above and below market lease intangibles, and lease termination fees. Adjusted NOI is sometimes referred to as "cash NOI."

<sup>&</sup>lt;sup>(2)</sup> Same property portfolio ("SPP") statistics allow management to evaluate the performance of the Company's real estate portfolio under a consistent population, which eliminates the changes in the composition of the Company's portfolio of properties. The Company identifies its SPP as stabilized properties that remained in operations and were consistently reported as leased properties or operating properties (RIDEA) for the duration of the year-over-year comparison periods presented. Accordingly, it takes a stabilized property a minimum of 12 months in operations under a consistent reporting structure to be included in the Company's SPP. SPP NOI excludes certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.

# Projected Future Operations<sup>(1)</sup> (Unaudited)

	20	12
	Low	High
Diluted earnings per common share	\$ 1.79	\$ 1.85
Real estate depreciation and amortization	0.86	0.86
DFL depreciation	0.03	0.03
Gain on sales of real estate	(0.01)	(0.01)
Joint venture FFO adjustments	0.01	0.01
Diluted FFO per common share	\$ 2.68	\$ 2.74
Preferred stock redemption charge	0.03	0.03
Merger-related items <sup>(2)</sup>	0.02	0.02
Impairments	0.02	0.02
Diluted FFO as adjusted per common share	\$ 2.75	\$ 2.81
Amortization of net below market lease intangibles and deferred revenues	(0.01)	(0.01)
Amortization of deferred compensation	0.05	0.05
Amortization of deferred financing costs, net	0.04	0.04
Straight-line rents	(0.10)	(0.10)
DFL accretion <sup>(3)</sup>	(0.23)	(0.23)
DFL depreciation	(0.03)	(0.03)
Leasing costs and tenant and capital improvements	(0.14)	(0.14)
Joint venture and other FAD adjustments <sup>(3)</sup>	(0.13)	(0.13)
Diluted FAD per common share	\$ 2.20	\$ 2.26

<sup>(1)</sup> Except as otherwise noted above, the foregoing projections reflect management's view of current and future market conditions, including assumptions with respect to rental rates, occupancy levels, development items and the earnings impact of the events referenced in this release. Except as otherwise noted, these estimates do not reflect the potential impact of future dispositions, other impairments or recoveries, the future bankruptcy or insolvency of our operators, lessees, borrowers or other obligors, the effect of any future restructuring of our contractual relationships with such entities, gains or losses on marketable securities, ineffectiveness related to our cash flow hedges, or existing and future litigation matters including the possibility of larger than expected litigation costs and related developments. There can be no assurance that our actual results will not differ materially from the estimates set forth above. The aforementioned ranges represent management's best estimate of results based upon the underlying assumptions as of the date of this press release. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments.

<sup>(2)</sup> Merger-related items of \$0.02 per share associated with the Senior Housing Portfolio Acquisition include direct transaction costs and the impact of the negative carry related to prefunding the transaction from the \$1.0 billion, or 22 million shares, common stock offering completed on October 19, 2012 on the calculation of weighted average shares. Proceeds from this offering will be used to fund the Senior Housing Portfolio Acquisition.

<sup>(3)</sup> Our ownership interest in HCR ManorCare OpCo is accounted for using the equity method, which requires an ongoing elimination of DFL income that is proportional to our ownership in HCR ManorCare OpCo. Further, our share of earnings from HCR ManorCare OpCo (equity income) increases for the corresponding elimination of related lease expense recognized at the HCR ManorCare OpCo level, which we present as a non-cash joint venture FAD adjustment.



# **Supplemental Information** September 30, 2012 (Unaudited)



Palm Harbor, FL



Olympia Fields, IL



San Diego, CA



Nashville, TN

#### **Table of Contents**

Company Information	1
Summary	2
Funds From Operations	3
Funds Available for Distribution	4
Capitalization	5
Credit Profile	6-7
Indebtedness and Ratios	8
Investments and Dispositions	9
Development	10
Owned Portfolio	
Portfolio summary	12
Portfolio concentrations	13
Same property portfolio	14
Lease expirations and debt investment maturities	15
Owned Senior Housing Portfolio	
Investments and operator concentration	16
Trends	17
Owned Post-Acute/Skilled Nursing Portfolio	
Investments and operator concentration	18
Trends and HCR ManorCare information	19
Owned Life Science Portfolio	
Investments, tenant concentration and trends	20
Selected lease expirations and leasing activity	21
Owned Medical Office Portfolio	
Investments and trends	22
Leasing activity	23
Owned Hospital Portfolio	
Investments and operator concentration	24
Trends	
Investment Management Platform	
Reporting Definitions and Reconciliations of Non-GAAP Measures	27-32

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this supplemental information which are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include among other things the Company's estimate of (i) completion dates, stabilization dates, rentable square feet and total investment for development projects in progress, and (ii) rentable square feet for land held for development. These statements are made as of the date hereof, are not guarantees of future performance and are subject to known and unknown risks, uncertainties, assumptions and other factors—many of which are out of the Company and its management's control and difficult to forecast—that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to: national and local economic conditions; continued volatility in the capital markets, including changes in interest rates and the availability and cost of capital, which changes and volatility affect opportunities for profitable investments; the Company's ability to access external sources of capital when desired and on reasonable terms; the Company's ability to manage its indebtedness levels; changes in the terms of the Company's indebtedness; the Company's ability to maintain its credit ratings; the potential impact of existing and future litigation matters, including the possibility of larger than expected litigation costs and related developments; the Company's ability to successfully integrate the operations of acquired companies; risks associated with the Company's investments in joint ventures and unconsolidated entities, including its lack of sole decision-making authority and its reliance on its joint venture partners' financial condition and continued cooperation; competition for lessees and mortgagors (including new leases and mortgages and the renewal or rollover of existing leases); the Company's ability to reposition its properties on the same or better terms if existing leases are not renewed or the Company exercises its right to replace an existing operator or tenant upon default; continuing reimbursement uncertainty in the post-acute/skilled nursing segment; competition in the senior housing segment specifically and in the healthcare industry in general; the ability of the Company's operators and tenants from its senior housing segment to maintain or increase their occupancy levels and revenues; the ability of the Company's lessees and mortgagors to maintain the financial strength and liquidity necessary to satisfy their respective obligations to the Company and other third parties; the bankruptcy, insolvency or financial deterioration of the Company's operators, lessees, borrowers or other obligors; changes in healthcare laws and regulations, including the impact of future or pending healthcare reform, and other changes in the healthcare industry which affect the operations of the Company's lessees or obligors, including changes in the federal budget resulting in the reduction or nonpayment of Medicare or Medicaid reimbursement rates; the Company's ability to recruit and retain key management personnel; costs of compliance with regulations and environmental laws affecting the Company's properties; changes in tax laws and regulations; changes in the financial position or business strategies of HCR ManorCare; the Company's ability and willingness to maintain its qualification as a REIT due to economic, market, legal, tax or other considerations; changes in rules governing financial reporting, including new accounting pronouncements; and other risks described from time to time in the Company's Securities and Exchange Commission filings. The Company assumes no, and hereby disclaims any, obligation to update any of the foregoing or any other forward-looking statements as a result of new information or new or future developments, except as otherwise required by law.



# Company Information<sup>(1)</sup>

#### **Board of Directors**

James F. Flaherty III

Chairman and Chief Executive Officer HCP, Inc.

Christine N. Garvey

Former Global Head of Corporate Real Estate Services, Deutsche Bank AG

David B. Henry

Vice Chairman, President and Chief Executive Officer, Kimco Realty Corporation

Lauralee E. Martin

James F. Flaherty III

Chief Executive Officer Jonathan M. Bergschneider

**Executive Vice President** 

**Executive Vice President and** 

Life Science Estates

Paul F. Gallagher

Chairman and

Chief Operating and Financial Officer Jones Lang LaSalle Incorporated

Michael D. McKee Chief Executive Officer Bentall Kennedy U.S., L.P.

Peter L. Rhein

Partner, Sarlot & Rhein

Kenneth B. Roath

Chairman Emeritus, HCP, Inc.

Joseph P. Sullivan

Chairman Emeritus of the Board of Advisors

**RAND** Health

#### Senior Management

Thomas M. Klaritch

**Executive Vice President** Medical Office Properties

James W. Mercer

**Executive Vice President, General Counsel** 

and Corporate Secretary

Timothy M. Schoen **Executive Vice President and** 

Chief Financial Officer

Susan M. Tate

**Executive Vice President** Post-Acute and Hospitals

Kendall K. Young

**Executive Vice President** 

Senior Housing

#### Other Information

San Francisco Office

400 Oyster Point Boulevard, Suite 409 South San Francisco, CA 94080-1920

Edward J. Henning **Executive Vice President** 

Chief Investment Officer

Thomas D. Kirby

**Executive Vice President** Acquisitions and Valuations

**Corporate Headquarters** 

3760 Kilroy Airport Way, Suite 300 Long Beach, CA 90806-2473 (562) 733-5100

Nashville Office

3000 Meridian Boulevard, Suite 200 Franklin, TN 37067-6388

The information in this supplemental information package should be read in conjunction with the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other information filed with the Securities and Exchange Commission ("SEC"). The Reporting Definitions and Reconciliations of Non-GAAP Measures are an integral part of the information presented herein.

On the Company's internet website, www.hcpi.com, you can access, free of charge, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained on its website is not incorporated by reference into, and should not be considered a part of, this supplemental information package. In addition, the SEC maintains an internet website that contains reports, proxy and information statements, and other information regarding issuers, including HCP, that file electronically with the SEC at www.sec.gov.

For more information, contact Timothy M. Schoen, Executive Vice President and Chief Financial Officer at (562) 733-5309.

<sup>(1)</sup> As of October 26, 2012.




1


# Summary


Dollars in thousands, except per share data	Three Mor			Nine Months Ended September 30,				
	 2012	Dei 30	<u>,,                                   </u>		2012	Dei 3	2011	
Revenues	\$ 475,482	\$	441,229	\$	1,393,206	\$	1,254,757	
NOI	392,077		382,496		1,169,387		1,002,850	
Adjusted (Cash) NOI	356,450		344,000		1,063,715		902,303	
YoY SPP Adjusted (Cash) NOI % Change	3.6%		4.5%(1)		3.8%		4.6%(1	
Adjusted EBITDA	\$ 405,622	\$	384,828	\$	1,195,684	\$	1,086,662	
Diluted FFO per common share	0.67		0.63		2.01		1.83	
Diluted FFO as adjusted per common share	0.69		0.67		2.05		2.02	
Diluted FAD per common share	0.55		0.53		1.65		1.65	
Diluted EPS	0.45		0.41		1.36		1.14	
Dividends declared per common share	\$ 0.50	\$	0.48	\$	1.50	\$	1.44	
FFO as adjusted payout ratio	72%		72%		73%		71%	
FAD payout ratio	91%		91%		91%		87%	
Financial leverage	40%		41%		40%		41%	
Adjusted fixed charge coverage	3.7x		3.3x		3.5x		3.0x	

Total properties:	September 30, 2012	December 31, 2011		
Senior housing	312	314		
Post-acute/skilled nursing	313	313		
Life science	113	108		
Medical office	270	254		
Hospital	21	21		
Total	1,029	1,010		

### Portfolio Income from Assets Under Management(2)







SPP adjusted (cash) NOI growth amounts are presented as originally reported.
 Represents adjusted NOI from real estate owned by HCP, interest income from debt investments and HCP's pro rata share of adjusted NOI from real estate owned by the Company's Investment Management Platform, excluding assets under development and land held for development, for the nine months ended September 30, 2012.
 Represents the historical cost of real estate owned by HCP, the carrying amount of debt investments and 100% of the cost of real estate owned by the Company's Investment Management Platform, excluding assets held for sale and under development and land held for development, at September 30, 2012.





<sup>(1)</sup> SPP adjusted (cash) NOI growth amounts are presented as originally reported.

#### **Funds From Operations**

Dollars and shares in thousands, except per share data

Dollars and shares in thousands, except per share data							
	Three Mon Septeml			Nine Months Ended September 30,			
	 2012	<del>50. 0.</del>	2011		2012		<del>2</del> 011
Net income applicable to common shares	\$ 195,629	\$	166,367	\$	572,352	\$	453,306
Depreciation and amortization of real estate, in-place lease and other intangibles:	•		·		•		·
Continuing operations	88,686		86,672		259,039		265,742
Discontinued operations	1,453		1,884		7,300		4,286
DFL depreciation	3,234		2,874		9,426		5,879
Gain on sales of real estate	_		_		(2,856)		— (7.7(0)
Gain upon consolidation of joint venture	(10.00()		(17.050)				(7,769)
Equity income from unconsolidated joint ventures	(13,396)		(17,050)		(42,803)		(32,798)
FFO from unconsolidated joint ventures Noncontrolling interests' and participating securities' share in	16,043		19,574		50,495		40,408
earnings	3,414		3,822		11,224		14,553
Noncontrolling interests' and participating securities' share in FFO	 (4,821)		(4,572)		(15,512 <sub>)</sub>		(16,385)
FFO applicable to common shares	\$ 290,242	\$	259,571	\$	848,665	\$	727,222
Distributions on dilutive convertible units	 3,148		3,048		9,397		9,066
Diluted FFO applicable to common shares	\$ 293,390	\$	262,619	\$	858,062	\$	736,288
Weighted average shares used to calculate diluted FFO per share	437,043		414,590		427,388		402,967
Diluted FFO per common share	\$ 0.67	\$	0.63	\$	2.01	\$	1.83
Dividends declared per common share	\$ 0.50	\$	0.48	\$	1.50	\$	1.44
FFO payout ratio	74.6%		76.2%		74.6%		78.7%
Impact of adjustments to FFO:							
Preferred stock redemption charge <sup>(1)</sup>	\$ _	\$	_	\$	10,432	\$	_
Merger-related items <sup>(2)</sup>	_		_		_		26,596
Impairments <sup>(3)</sup>	 7,878		15,400		7,878		15,400
	\$ 7,878	\$	15,400	\$	18,310	\$	41,996
FFO as adjusted applicable to common shares	\$ 298,120	\$	274,971	\$	866,975	\$	769,218
Distributions on dilutive convertible units and other	 3,127		3,011		9,345		8,927
Diluted FFO as adjusted applicable to common shares	\$ 301,247	\$	277,982	\$	876,320	\$	778,145
Weighted average shares used to calculate diluted FFO as adjusted per share	 437,043		414,590		427,388		385,693 <sup>(4)</sup>
Diluted FFO as adjusted per common share	\$ 0.69	\$	0.67	\$	2.05	\$	2.02 (4)
FFO as adjusted payout ratio	72.5%		71.6%	•	73.2%		71.3%
1 1 /							

(4) \$0.15 per share of merger-related items attributable to the HCR ManorCare Acquisition include the following:

#### See Reporting Definitions and Reconciliations of Non-GAAP Measures



<sup>🕦</sup> In connection with the redemption of the Company's preferred stock, during the nine months ended September 30, 2012, the Company incurred a one-time, non-cash redemption charge of \$10.4 million, or \$0.02 per share, related to the original issuance costs.

<sup>(2)</sup> Merger-related items for the nine months ended September 30, 2011 are attributable to the HCR ManorCare Acquisition (incurred from January 1st through April 6th 2011), which include the following: (i) \$26.8 million of direct transaction costs, (ii) \$23.9 million of interest expense associated with the \$2.4 billion senior unsecured notes offering completed on January 24, 2011, which proceeds were obtained to prefund the HCR ManorCare Acquisition, partially offset by (iii) \$24.1 million of income related to gains upon the reinvestment of the Company's debt investment in HCR ManorCare and other miscellaneous items.

The third quarter 2012 impairment charge of \$7.9 million, or \$0.02 per share, relates to the pending sale of a land parcel in our life science segment. The third quarter 2011 impairment charge of \$15.4 million, or \$0.04 per share, relates to our senior secured loan to Cirrus Health.

<sup>(</sup>ii) \$0.07 per share of direct transaction costs that is discussed in footnote 2(ii);
(ii) (\$0.07) per share of income related to gains upon the reinvestment of the Company's debt investment in HCR ManorCare debt and other miscellaneous items that are discussed in footnote 2(iii);

<sup>(</sup>iii) \$0.15 per share of negative carry related to prefunding activities of: (a) \$0.09 per share from the Company's December 2010 46 million share common stock offering and 30 million shares from the Company's March 2011 common stock offering (excludes 4.5 million shares sold to the underwriters upon exercise of their option to purchase additional shares), which issuances increased weighted average shares by 26 million for the nine months ended September 30, 2011; and (b) \$0.06 per share for additional interest expense related to the \$2.4 billion senior unsecured notes offering that is discussed in footnote 2(ii). Proceeds from these offerings were used to prefund a portion of the cash consideration for the HCR ManorCare Acquisition.

### **Funds Available for Distribution**

Dollars and shares in thousands, except per share data

, , ,	Three Months Ended September 30,					ded ,		
		2012		2011	2012			2011
FFO as adjusted applicable to common shares	\$	298,120	\$	274,971	\$	866,975	\$	769,218
Amortization of above and below market lease intangibles, net		(533)		(1,178)		(1,855)		(3,271)
Amortization of deferred compensation		5,540		5,081		16,947		15,286
Amortization of deferred financing costs, net		3,956		3,716		12,415		10,065
Straight-line rents		(11,821)		(14,024)		(33,608)		(46,936)
DFL accretion <sup>(1)</sup>		(23,433)		(23,571)		(71,072)		(48,508)
DFL depreciation		(3,234)		(2,874)		(9,426)		(5,879)
Deferred revenues – tenant improvement related		(424)		(491)		(1,257)		(2,134)
Deferred revenues – additional rents (SAB 104)		356		284		2,358		850
Leasing costs and tenant and capital improvements		(15,705)		(10,832)		(42,817)		(31,772)
Joint venture and other FAD adjustments <sup>(1)</sup>		(16,543)		(14,757)		(43,219)		(29,087)
FAD applicable to common shares	\$	236,279	\$	216,325	\$	695,441	\$	627,832
Distributions on dilutive convertible units		1,827		1,756		5,404		5,158
Diluted FAD applicable to common shares	\$	238,106	\$	218,081	\$	700,845	\$	632,990
Weighted average shares used to calculate diluted FAD per share		434,786		412,305		425,121		383,397
Diluted FAD per common share	\$	0.55	\$	0.53	\$	1.65	\$	1.65
Dividends declared per common share	\$	0.50	\$	0.48	\$	1.50	\$	1.44
FAD payout ratio		90.9%		90.6%		90.9%		87.3%

<sup>(1)</sup> For the three and nine months ended September 30, 2012, DFL accretion reflects an elimination of \$14.9 million and \$44.4 million, respectively. For the three and nine months ended September 30, 2011, DFL accretion reflects an elimination of \$14.4 million and \$27.7 million, respectively. Our ownership interest in HCR ManorCare OpCo is accounted for using the equity method, which requires an ongoing elimination of DFL income that is proportional to our ownership in HCR ManorCare OpCo. Further, our share of earnings from HCR ManorCare OpCo (equity income) increases for the corresponding elimination of related lease expense recognized at the HCR ManorCare OpCo level, which we present as a non-cash joint venture FAD adjustment.





# Capitalization

Dollars and shares in thousands, except price data							
• •	Total Debt						
		Sep	otember 30, 2012	D	ecember 31, 2011	Se	ptember 30, 2011
Bank line of credit	3	\$		\$	454,000	\$	375,000
Term loan <sup>(1)</sup>			221,214		_		_
Senior unsecured notes			5,913,690		5,416,063		5,415,097
Mortgage debt			1,684,514		1,715,039		1,730,102
Mortgage debt on assets held for sale			_		49,532		49,938
Other debt			84,580		87,985		89,325
Consolidated debt	_		7,903,998		7,722,619		7,659,462
HCP's share of unconsolidated debt <sup>(2)</sup>			141,465		143,196		143,916
Total debt	3	\$	8,045,463	\$	7,865,815	\$	7,803,378

**Total Market Capitalization** 

	September 30, 2012						
	Shares		Value Total Va				
Common stock (NYSE: HCP)	429,980	\$	44.48	\$	19,125,510		
Convertible partnerships (DownREITs) <sup>(3)</sup>	6,412				285,206		
Total market equity				\$	19,410,716		
Consolidated debt					7,909,647		
Total market equity and consolidated debt				\$	27,320,363		
HCP's share of unconsolidated debt <sup>(2)</sup>					141,465		
Total market capitalization				\$	27,461,828		

Common Stock and Equivalents

	Shares	Weighted Average Shares Three Months Ended September 30, 2012						
	Outstanding September 30, 2012	Diluted EPS	Diluted FFO	Diluted FFO As Adjusted	Diluted FAD			
Common stock Common equivalent securities:	429,980	429,557	429,557	429,557	429,557			
Restricted stock and units	1,756	321	321	321	321			
Dilutive impact of options	900	900	900	900	900			
Convertible partnership units	6,412	_	6,265	6,265	4,008			
Total common and equivalents	439,048	430,778	437,043	437,043	434,786			

**Weighted Average Shares** Nine Months Ended September 30, 2012


	• • • • • • • • • • • • • • • • • • • •	no monina Enaca e	opiciiibei ee, ze iz	
	Diluted	Diluted	Diluted FFO	Diluted
	EPS	FFO	As Adjusted	FAD
Common stock	420,049	420,049	420,049	420,049
Common equivalent securities:				
Restricted stock and units	278	278	278	278
Dilutive impact of options	1,077	1,077	1,077	1,077
Convertible partnership units	<u></u>	5,984	5,984	3,717
Total common and equivalents	421,404	427,388	427,388	425,121

<sup>(1)</sup> Represents £137 million translated into U.S. dollars as of September 30, 2012.
(2) Reflects the Company's pro rata share of amounts in the Investment Management Platform and HCR ManorCare OpCo.
(3) Convertible partnership (DownREIT) units are exchangeable for an amount of cash approximating the then-current market value of shares of the Company's common stock at the time of conversion or, at the Company's election, shares of the Company's common stock.



#### See Reporting Definitions and Reconciliations of Non-GAAP Measures

#### **Credit Profile**



Financial leverage, secured debt ratio and net debt to adjusted EBITDA are proforma to exclude the temporary benefit resulting from prefunding the HCR ManorCare acquisition in December 2010.




<sup>(1)</sup> As of and for the six months ended June 30, 2006 (12 months for adjusted fixed charge coverage). The Company completed the mergers with CNL Retirement Properties, Inc. and CNL Retirement Corp ("CNL") on October 5, 2006, with significant prefunding activities occurring in the quarter ended June 30, 2006; therefore, the Company refers to the period ended June 30, 2006 as "Pre-CNL Acquisition."


#### **Credit Profile**

#### Same Property NOI Growth 6% 4.8% 4.6% 4.6% 4.0% 3.6% 3.2% 4% 2.1%2.4% 2.6% 1.6%2.1% 2.0% 2% 0% 2005 2006 2007 2008 2009 2010 2011 3Q 2012 (2%) (0.6%)HCP<sup>(1)</sup> ■ Major Property Sectors<sup>(2)</sup> (2.8%)(4%)

#### **Total Gross Assets**



#### Liquidity(5)



#### **Credit Ratings (Senior Unsecured Debt)**

	Pre-CNL <sup>(3)</sup> Acquisition	2006	2007	2008	2009	2010	2011	3Q 2012
Moody's	Baa2	Baa3	Baa3	Baa3	Baa3	Baa3	Baa2	Baa2 (Stable)
Standard & Poor's	BBB+	BBB	BBB	BBB	BBB	BBB	BBB	BBB (Positive)
Fitch	BBB+	BBB	BBB	BBB	BBB	BBB	BBB+	BBB+ (Stable)

<sup>(1)</sup> HCP information is presented as originally reported and represents annual SPP cash NOI growth except for 3Q 2012, which is year-over-year three-month growth

Represents the availability under the Company's bank line of credit and cash and cash equivalents (unrestricted cash).





Major Property Sectors information was compiled by Green Street Advisors and is available in their Commercial Property Outlook report dated August 21, 2012 (the "Green Street Report"); this information represents the average annual same property NOI growth equally weighted for each of five major property sectors: apartment, industrial, mall, office, and strip center. The Company's definitions of SPP and NOI may not be comparable to the measures compiled in the Green Street Report, as different methodologies may be used to define or calculate inputs to the growth rates

As of and for the six months ended June 30, 2006. The Company completed the mergers with CNL Retirement Properties, Inc. and CNL Retirement Corp ("CNL") on October 5, 2006, with significant prefunding activities occurring in the quarter ended June 30, 2006; therefore, the Company refers to the period ended June 30, 2006 as "Pre-CNL Acquisition."

Total gross assets and liquidity are proforma to exclude the temporary benefit resulting from prefunding the HCR ManorCare acquisition in December 2010.

#### Dollars in thousands

#### Debt Maturities and Scheduled Principal Repayments (Amortization) September 30, 2012

			Senior					HCP's Share of		
	Bank Line		Unsecured		Mortgage		Consolidated	Unconsolidated		
	of Credit	Term Loan <sup>(1)</sup>	<u>Notes</u>	Rates <sup>(2)</sup>	Debt <sup>(3)</sup>	Rates <sup>(2)</sup>	Debt	Debt <sup>(4)</sup>	Rates <sup>(2)</sup>	Total Debt
2012 (3 months)	\$ —	\$ <u> </u>	\$ —	—%	\$ 8,715	—%	\$ 8,715	\$ 678	N/A%	\$ 9,393
2013	_	_	550,000	5.80	320,207	6.09	870,207	3,271	7.04	873,478
2014	_	_	487,000	3.22	184,495	5.76	671,495	849	N/A	672,344
2015	_	_	400,000	6.64	304,761	6.03	704,761	11,347	5.82	716,108
2016	_	221,214	900,000	5.07	293,175	6.87	1,414,389	47,057	6.05	1,461,446
2017	_	_	750,000	6.04	519,414	6.10	1,269,414	41,376	5.86	1,310,790
2018	_	_	600,000	6.83	5,915	5.90	605,915	37,036	5.00	642,951
2019	_	_	450,000	3.95	1,361	N/A	451,361	_	_	451,361
2020	_	_	· —	_	1,462	N/A	1,462	_	_	1,462
2021	_	_	1,200,000	5.53	8,832	5.38	1,208,832	_	_	1,208,832
Thereafter	_	_	600,000	5.08	47,778	5.17	647,778	_	_	647,778
Subtotal		221,214	5,937,000		1,696,115		7,854,329	141,614		7,995,943
Other debt <sup>(5)</sup>	_	· —	· · · · —		· · · · —		84,580	· —		84,580
(Discounts) and premiums, net		_	(23,310)		(11,601)		(34,911)	(149)		(35,060)
Total debt	<u> </u>	\$ 221,214	\$ 5,913,690		\$ 1,684,514		\$ 7,903,998	\$ 141,465		\$ 8,045,463
		<u> </u>						,		
Weighted average interest rate	N/A	2.00%	5.40%		6.14%		5.47%	5.85%		5.47%
<b>.</b>										
Weighted average maturity in years	3.45	3.83	6.11		3.80		5.55	4.37		5.53

Katios		
	September 30, 2012	December 31, 2011
Consolidated Debt/Consolidated Gross Assets	40.0%	41.0%
Financial Leverage (Total Debt/Total Gross Assets)	40.0%	41.0%
Consolidated Secured Debt/Consolidated Gross Assets	8.5%	9.4%
Secured Debt Ratio (Total Secured Debt/Total Gross Assets)	9.1%	10.0%
Fixed and variable rate ratios <sup>(7)</sup> :		
Fixed rate Total Debt	99.0%	93.1%
Variable rate Total Debt	1.0%	6.9%
	100.0%	100.0%

Dation

Covenants

The following is a summary of the financial covenants under the revolving line of credit facility at September 30, 2012.

	Bank Line of Credit				
Financial Covenants <sup>(6)</sup>	Requirement	Actual Compliance			
Leverage Ratio	No greater than 60%	41%			
Secured Debt Ratio	No greater than 30%	10%			
Unsecured Leverage Ratio	No greater than 60%	39%			
Fixed Charge Coverage Ratio (12 months)	No less than 1.50x	3.2x			

# See Reporting Definitions and Reconciliations of Non-GAAP Measures



<sup>(1)</sup> Represents £137 million translated into U.S. dollars as of September 30, 2012.

<sup>(2)</sup> Senior unsecured notes and mortgage debt weighted average effective rates relate to maturing amounts.

<sup>(3)</sup> Mortgage debt attributable to non-controlling interests at September 30, 2012 was \$66 million.

<sup>(4)</sup> Includes pro-rata share of mortgage and other debt in the Company's Investment Management Platform and HCR ManorCare OpCo. At September 30, 2012, 100% of the Company's Investment Management Platform's mortgage debt accrues interest at fixed rates. HCR ManorCare OpCo's debt accrues interest at LIBOR (subject to a floor of 150bps) plus 350bps.

<sup>(5)</sup> Represents non-interest bearing life care bonds and occupancy fee deposits at certain of the Company's senior housing facilities that have no scheduled maturities.

<sup>(6)</sup> Financial covenants for the revolving line of credit facility are calculated based on the definitions contained within the agreement and may be different than similar terms in the Company's Consolidated Financial Statements as provided in its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Compliance with certain of these financial covenants requires the inclusion of the Company's consolidated amounts and its proportionate share of unconsolidated investees.

<sup>(7) \$87</sup> million of variable-rate mortgages and £137 million term loan are presented as fixed-rate debt as the interest payments under such debt have been swapped (pay fixed and receive float).

### **Investments and Dispositions**

Dollars and square feet in thousands

#### Investments

	September 30, 2012					
Description	Thr	ree Months Ended	Nine Months Ended			
Purchase of marketable debt securities <sup>(1)</sup>	\$	_	\$	214,859		
Acquisitions of real estate and land		223,881		234,931		
Mezzanine loan funding <sup>(2)</sup>		100,000		100,000		
Total fundings for development, tenant and capital improvements <sup>(3)</sup>		46,917		125,575		
Construction loan commitment fundings		16,359		37,116		
Total investments	\$	387,157	\$	712,481		

Acquisitions of real estate and land for the nine months ended September 30, 2012

Location	Date	Capacity	Property Count	Segment	In	vestment
Durham, NC	May 15, 2012	115 sq. ft.	1	Life science	\$	8,050
Slidell, LA	May 30, 2012	12.6 acres	_	Hospital		3,000
Kokomo, IN	July 1, 2012	21 sq. ft.	_	Senior housing		3,860
N. Richland Hills, TX	July 30, 2012	80 sq. ft.	1	Medical office		13,500
Various	July 31, 2012	327 sq. ft.	6	Medical office		77,646
Scottsdale, AZ	August 7, 2012	398 sq. ft.	8	Medical office		79,754
Various	August 15, 2012	199 sq. ft.	4	Medical office		49,121
	•	•			\$	234,931

Dispositions for the nine months ended September 30, 2012

	-		Property	Sal	es Price,	
Location	Date	Capacity	Count	Segment	Net	of Costs
St. Louis, MO	February 29, 2012	44 sq. ft.	1	Medical office	\$	6,982

<sup>(3)</sup> The three months ended September 30, 2012, includes the following: (i) \$22.5 million of development, (ii) \$12.2 million of first generation tenant and capital improvements, and (iii) \$12.2 million of second generation tenant and capital improvements (excludes \$3.5 million of leasing costs). The nine months ended September 30, 2012, includes the following: (i) \$67.3 million of development, (ii) \$26.4 million of first generation tenant and capital improvements, and (iii) \$31.9 million of second generation tenant and capital improvements (excludes \$10.9 million of leasing costs).



#### See Reporting Definitions and Reconciliations of Non-GAAP Measures

<sup>(1)</sup> Senior unsecured notes of Four Seasons Health Care with an aggregate par value of £138.5 million, purchased at a discount for £136.8 million, and translated into U.S. dollars as of the acquisition

On July 31, 2012, the Company closed a mezzanine loan facility to lend up to \$205 million to Tandem Health Care, an affiliate of Formation Capital, as part of the recapitalization of a post-acute/skilled nursing portfolio. The Company funded \$100 million at closing and expects to fund an additional \$105 million between March 2013 and August 2013.

#### **Development Projects in Process**

Name of Project	Location	Segment	Estimated/ Actual Completion Date	Estimated Rentable Square Feet	Investment to Date(1)(3)	Estimated Total Investment	
Development	_						
2019 Stierlin Ct.	Mountain View, CA	Life science	1Q 2013	70	\$ 12,544	\$ 21,298	
Ridgeview	Poway, CA	Life science	2Q 2014	115	11,141	22,937	
Redevelopment							
1030 Massachusetts Avenue	Cambridge, MA	Life science	3Q 2012	75	35,194	39,992	
Durham Research Lab	Durham, NC	Life science	3Q 2013	53	12,424	24,586	
Carmichael	Durham, NC	Life science	3Q 2013	38	3,281	16,397	
Westpark Plaza	Plano, TX	Medical office	1Q 2012	70	13,824	17,159	
Innovation Drive	San Diego, CA	Medical office	3Q 2012	84	28,535	33,689	
Alaska	Anchorage, AK	Medical office	4Q 2012	49	7,873	11,763	
Conroe	Conroe, TX	Medical office	4Q 2012	37	5,830	9,316	
Folsom	Sacramento, CA	Medical office	1Q 2013	92	32,104	39,251	
Fresno	Fresno, CA	Hospital	1Q 2013	N/A	12,891	20,554	
	Total				\$ 175,641	\$ 256,942	

#### Land Held for Development

Location	Segment	Gross Site Acreage	Estimated Rentable Square Feet
So. San Francisco, CA	Life science	50	1,666
Carlsbad, CA	Life science	41	690
Poway, CA	Life science	64	1,029
Various	Various	19	93
		174	
Investment-to-date <sup>(2)(3)</sup>		\$ 375,980	

#### **Projects Placed in Service**

Name of Project	Location	Segment	Date Placed in Service	Rentable Square Feet	Inve	estment <sup>(4)</sup>	Percentage Leased
Modular Labs IV	So. San Francisco, CA	Life science	1Q 2012	97	\$	56,179	75
Soledad	San Diego, CA	Life science	1Q 2012	28		13,208	100
Conroe <sup>(5)</sup>	Conroe, TX	Medical office	2Q 2012	33		3,824	100
Knoxville	Knoxville, TN	Medical office	2Q - 3Q 2012	35		8,684	68
Alaska <sup>(5)</sup>	Anchorage, AK	Medical office	3Q 2012	43		7,854	100
	_			236	\$	89,749	

<sup>(4)</sup> Represents the investment as of the date the respective property was placed in service.
(5) Represents approximately 50% of the Conroe and Alaska facilities placed in service in June 2012 and September 2012, respectively.





<sup>(1)</sup> Investment-to-date of \$176 million includes the following: (i) \$71 million in development costs and construction in progress, (ii) \$78 million of buildings and (iii) \$27 million of land.
(2) Investment-to-date of \$376 million includes the following: (i) \$272 million in land (ii) \$104 million in development costs and construction in progress.
(3) Development costs and construction in progress of \$230 million presented on the Company's consolidated balance sheet at September 30, 2012, include the following: (i) \$71 million of costs for development projects in process; (ii) \$104 million of costs for land held for development; and (iii) \$55 million for tenant and other facility related improvement projects in process.

# Portfolio Information September 30, 2012 (Unaudited)

# **Owned Portfolio Summary**

As of and for the nine months ended September 30, 2012, dollars and square feet in thousands

#### Portfolio Summary by Investment Product

Leased	Property			Age		Occupancy	EBITDA	R <sup>(1)</sup>	EBITDARM(1)		
<u>Properties</u>	Count	Investment	NOI	(Years)	Capacity	<u></u>	Amount	CFC	Amount	CFC	
Senior housing	291	\$ 5,070,948	\$ 340,581	16	30,595 Units	85.3	\$ 388,113	1.12 x	\$ 466,015	1.34 x	
Post-acute/skilled	313	5,643,103	403,654	33	41,731 Beds	85.9	55,698	1.49 x	75,716	2.02 x	
Life science	109	3,350,308	177,339	19	7,001 Sq. Ft.	90.0	N/A	N/A	N/A	N/A	
Medical office	204	2,536,583	148,030	19	14,039 Sq. Ft.	91.5	N/A	N/A	N/A	N/A	
Hospital	17	650,130	60,530	26	2,410 Beds	52.8	382,116	4.76 x	417,700	5.20 x	
	934	\$ 17,251,072	\$1,130,134	23							

Operating Properties	Property			Age Occupan							
(RIDEA)	Count	<u>  Ir</u>	vestment		NOI	(Years)	Capacity	<u></u>			
Senior housing <sup>(2)</sup>	21	\$	752,591	\$	39,253	22	5,008 Units	86.1			

Debt Investments		Investment		nterest ncome
Senior housing		\$ 49,237	\$	1,686
Post-acute/skilled <sup>(3)</sup>		328,570		9,842
Hospital <sup>(4)</sup>		84,139		785
		\$ 461,946	\$	12,313
Total	955	\$ 18,465,609	\$ 1	,181,700

#### Portfolio NOI, Adjusted NOI and Interest Income

Three Months Ended September 30, 2012

RIDEA		ental and RIDEA Revenues	_	Operating Expenses	NOI <sup>(5)</sup>	 Adjusted NOI	 Interest Income	Adjusted NOI and Interest Income	
Senior housing <sup>(2)</sup>	\$	150,932	\$	24,872	\$ 126,060	\$ 113,592	\$ 876	\$	114,468
Post-acute/skilled		135,508		154	135,354	116,898	9,135		126,033
Life science		71,194		11,791	59,403	56,341	_		56,341
Medical office		85,800		34,948	50,852	49,669	_		49,669
Hospital		21,310		902	 20,408	 19,950	 267		20,217
	\$	464,744	\$	72,667	\$ 392,077	\$ 356,450	\$ 10,278	\$	366,728

Nine Months Ended September 30, 2012

Segment	Rental and RIDEA Revenues		RIDEA Operating			NOI <sup>(5)</sup>	 Adjusted NOI	Interest Income	Adjusted NOI and Interest Income		
Senior housing <sup>(2)</sup>	\$	449,760	\$	69,926	\$	379,834	\$ 342,368	\$ 1,686	\$	344,054	
Post-acute/skilled		404,180		526		403,654	346,900	9,842		356,742	
Life science		215,569		38,230		177,339	171,179	_		171,179	
Medical office		246,661		98,631		148,030	144,272	_		144,272	
Hospital		63,300		2,770		60,530	 58,996	 785		59,781	
	\$	1,379,470	\$	210,083	\$	1,169,387	\$ 1,063,715	\$ 12,313	\$	1,076,028	

<sup>[1]</sup> EBITDAR, EBITDARM and their respective CFC are not presented for the disaggregated HCR ManorCare senior housing and post-acute/skilled nursing portfolios as the combined portfolio is cross-collateralized under a single master lease. See HCR ManorCare Leased Portfolio Summary on page 19 of this report.

#### See Reporting Definitions and Reconciliations of Non-GAAP Measures



Brookdale Senior Living manages 21 assets on behalf of the Company under a RIDEA structure. For the three months ended September 30, 2012, revenues and operating expenses were \$36.1 million and \$24.1 million, respectively. For the nine months ended September 30, 2012, revenues and operating expenses were \$106.8 million and \$67.5 million, respectively.

Includes senior unsecured notes of Four Seasons Health Care with an aggregate par value of £138.5 million, purchased at a discount for £136.8 million with a carrying value translated into U.S.

dollars of \$221.0 million as of September 30, 2012.

(4) Includes a senior secured loan to Delphis Operations, LP ("Delphis") that was placed on non-accrual status effective January 1, 2011 with a carrying value of \$69 million at September 30, 2012. For additional information regarding the senior secured loan to Delphis see Note 7 to the Consolidated Financial Statements for the nine months ended September 30, 2012 included in the Company's Quarterly Report on Form 10-Q filed with the SEC.

<sup>(5)</sup> NOI attributable to non-controlling interests for the three and nine months ended September 30, 2012 was \$2.2 million and \$6.9 million, respectively.

# **Owned Portfolio Concentrations**

As of and for the nine months ended September 30, 2012, dollars in thousands

#### **Geographic Diversification of Properties**

Investment by State	Total Properties	Senior Housing	Post-Acute/ Skilled	Life Science	Medical Office	 Hospital	Total	% of Total
CA	153	\$ 648,931	\$ 269,712	\$ 3,224,405	\$ 215,026	\$ 128,545	\$ 4,486,619	25
TX	97	689,018	104,021	_	709,229	228,986	1,731,254	10
FL	95	830,517	540,923	_	156,010	62,450	1,589,900	9
PA	54	262,129	1,199,698	_	_	_	1,461,827	8
IL	51	505,570	696,034	_	13,490	_	1,215,094	7
ОН	72	215,144	678,624	_	9,421	_	903,189	5
MI	38	176,519	573,977	_	_	_	750,496	4
MD	34	301,123	229,638	_	30,061	_	560,822	3
VA	29	320,239	174,815	_	42,742	_	537,796	3
NJ	21	378,430	98,832	_	_	_	477,262	3
Other	311	1,495,919	1,076,829	125,903	1,360,604	230,149	4,289,404	23
Total	955	\$ 5,823,539	\$ 5,643,103	\$ 3,350,308	\$ 2,536,583	\$ 650,130	\$ 18,003,663	100

NOI by State	Total Properties	-	enior ousing	st-Acute/ Skilled	Life Science	Medical Office	<u> </u>	lospital	Total	% of Total
CA	153	\$	45,070	\$ 19,218	\$ 166,974	\$ 10,067	\$	12,506	\$ 253,835	22
TX	97		47,764	6,431	_	39,843		19,784	113,822	10
FL	95		54,139	37,749	_	10,763		5,870	108,521	9
PA	54		15,959	85,628	_	_		_	101,587	9
IL	51		31,750	47,959	_	990		_	80,699	7
ОН	72		14,176	50,304	_	525		_	65,005	6
MI	38		11,951	38,956	_	_		_	50,907	4
MD	34		19,181	16,230	_	1,950		_	37,361	3
VA	29		17,814	12,958	_	2,647		_	33,419	3
СО	26		12,838	5,779	_	11,934		1,072	31,623	3
Other	306	1	109,192	82,442	 10,365	69,311		21,298	292,608	24
Total	955	\$ 3	379,834	\$ 403,654	\$ 177,339	\$ 148,030	\$	60,530	\$ 1,169,387	100

#### **Operator/Tenant Diversification**

	Primary	Annualized Re	evenues <sup>(1)</sup>
Company	Segment	Amount	%
HCR ManorCare	Post-acute/skilled	\$ 489,038	32
Brookdale Senior Living	Senior housing	128,068	8
Emeritus Corporation	Senior housing	102,576	7
Sunrise Senior Living	Senior housing	86,700	6
HCA	Hospital	50,764	3
Amgen	Life science	42,247	3
Genentech	Life science	38,653	2
Four Seasons Health Care	Post-acute/skilled	26,830	2
Kindred	Post-acute/skilled	16,995	1
Capital Senior Living	Senior housing	16,106	1
Other		552,753	35
		\$ 1,550,730	100

<sup>(1)</sup> The most recent monthly base rent (including additional rent floors), cash income from direct financing leases and/or interest income annualized for 12 months. Annualized revenues for operating properties under a RIDEA structure are based on the most recent quarter's NOI annualized for 12 months. For additional details regarding "annualized revenues," see reporting definitions.





# **Owned Same Property Portfolio**

As of September 30, 2012, dollars and square feet in thousands

Three-	 	CDD

		Total		Senior Housing		Post-Acute/ Skilled		Life Science		Medical Office		Hospital
Property count		905		291		313		101		184		16
Investment	\$	16,828,635	\$	5,067,088	\$	5,643,103	\$	3,215,177	\$	2,292,882	\$	610,385
Percent of property portfolio (by investment)		93.5%		87.0%		100.0%		96.0%		90.4%		93.9%
Capacity				30,595 Units		41,731 Beds		6,685 Sq. Ft.		12,880 Sq. Ft.	2	,379 Beds
Year-Over-Year Three-Month SPP												
Occupancy:										/		
September 30, 2012				85.3%		85.4%		91.4%		91.8%		54.3%
September 30, 2011 <b>% change</b>				84.9% <b>0.4%</b>		87.1% <b>(1.7%)</b>		91.1% <b>0.3%</b>		90.9% <b>0.9%</b>		53.1% <b>1.2%</b>
NOI % change		2.0%		0.7%		2.4%		2.6%		2.5%		4.1%
Adjusted NOI:												
September 30, 2012	\$	344,235	\$	102,154	\$	116,898	\$	57,032	\$	48,796	\$	19,355
September 30, 2011	\$	332,201	\$		\$	112,885		53,324		47,479		18,480
Adjusted NOI % change	_	3.6%	_	2.1%	_	3.6%	_	7.0%	_	2.8%	_	4.7%
Sequential Three-Month SPP												
Occupancy:												
September 30, 2012				85.3%		85.4%		91.4%		91.8%		54.3%
June 30, 2012				85.5%		85.9%		91.5%		91.6%		56.3%
% change				(0.2%)		(0.5%)		(0.1%)		0.2%		(2.0%
NOI % change	_	0.2%	_	1.0%	_	0.6%	_	0.8%	_	(1.0%)		(6.0%
Adjusted NOI:												
September 30, 2012	\$	344,235	\$	102,154	\$	116,898	\$	57,032	\$	48,796	\$	19,355
June 30, 2012	\$	344,689		101,922	\$	116,835	\$	56,409	\$	48,965	\$	20,558
Adjusted NOI % change	_	(0.1%)	_	0.2%	_	0.1%	_	1.1%	_	(0.3%)	_	(5.9%
		Year-C	Ονε	er-Year Nine-M								
		Total		Senior Housing		Post-Acute/ Skilled		Life Science		Medical Office		Hospital
Property count		566		221		45		101	_	183		16
Investment	\$	10,467,930	\$	4,133,640	\$	247,668	\$	3,215,177	\$	2,261,060	\$	610,385
Percentage of property portfolio (by investment)	•	58.1%	•	71.0%	•	4.4%	•	96.0%	•	89.1%	•	93.9%
Capacity				25,081 Units		5,300 Beds		6,685 Sq. Ft.		12,747 Sq. Ft.	2	,379 Beds
Year-Over-Year Nine-Month SPP												
Occupancy:						•				/		
September 30, 2012				85.6%		84.4%		91.4%		91.8%		54.3%
September 30, 2011				85.2%		85.5% /1.10/\		91.1%		90.8%		53.1%
% change NOI % change		0.5%		<b>0.4%</b> (0.9%)		<b>(1.1%)</b> (1.1%)		<b>0.3%</b> 0.6%		1.0% 2.1%		1.2% 3.4%
Adjusted NOI:	_	0.5%	_	(0.770)		(1.170)		0.076		Z.170		3.470
September 30, 2012	\$	658,002	\$	255,221	\$	28,310	\$	173,293	\$	143,956	\$	57,222
September 30, 2011	\$	633,654	\$	250,124	\$	27,634	\$	161,088	\$	139,792	\$	55,016





# **Owned Portfolio Lease Expirations and Debt Investment Maturities**

At September 30, 2012, dollars and square feet in thousands

												Exp	iration Ye	ar <sup>(1)</sup>									
Segment	<u>Total</u>		2012(2)	_	2013	_	2014		2015		2016	_	2017		2018		2019		2020	_	2021		hereafter
Lease Expirations																							
Senior housing <sup>(3)</sup> : Properties Annualized revenues	29 \$ 410,69		_	\$	_	\$	5 5,091	\$	1 209	\$	15 22,937	\$	12 20,245	\$	47 87,130	\$	10 14,121	\$	35 55,182	\$	16 17,724	\$	150 188,051
Post-acute/skilled: Properties Annualized revenues	31 \$ 468,76		_	\$	=	\$	9 7,197	\$	1 450	\$	1 320	\$	9 8,607	\$	3 2,806	\$	12 10,121	\$	9 8,351	\$	_	\$	269 430,913
<b>Life science:</b> Square feet Annualized revenues	6,30 \$ 230,84		43 166	\$	437 11,238	\$	342 10,244	\$	691 24,047	\$	259 6,782	\$	810 26,999	\$	529 25,741	\$	121 4,147	\$	929 41,937	\$	557 31,501	\$	1,582 48,045
Medical office: Square feet Annualized revenues	12,84 \$ 279,99		702 16,178	\$	1,949 38,668	\$	1,734 39,713	\$	1,522 34,080	\$	1,249 25,906	\$	1,371 30,118	\$	1,148 23,220	\$	827 18,008	\$	892 20,694	\$	367 8,790	\$	1,087 24,617
Hospital: Properties Annualized revenues	1 \$ 67,61		_	\$	1 2,611	\$	3 16,018	\$	_	\$	_	\$	2 4,776	\$		\$	5 7,113	\$	_ _	\$	1 1,650	\$	5 35,451
Total annualized revenues	\$1,457,91	\$	16,344	\$	52,517	\$	78,263	\$	58,786	\$	55,945	\$	90,745	\$	138,897	\$	53,510	\$	126,164	\$	59,665	\$	727,077
% of Total	10	<u> </u>	1	_	4	_	5	_	4	_	4	_	6	_	10	_	4	_	9	_	4	_	49
Debt Investment Maturities																							
Senior housing: Annualized revenues	\$ 3,91	5 \$	_	\$	_	\$	_	\$	_	\$	3,414	\$	501	\$	_	\$	_	\$	_	\$	_	\$	_
Post-acute/skilled: Annualized revenues	\$ 39,91	9 \$	_	\$	925	\$	164	\$	_	\$	_	\$	12,000	\$	_	\$	_	\$	26,830	\$	_	\$	_
<b>Hospital<sup>(4)</sup></b> Annualized revenues	\$ 1,07	1 \$	_	\$	_	\$	_	\$	1,071	\$	_	\$	_	\$	_	\$	_	\$	_	\$	_	\$	_
Total annualized revenues	\$ 44,90	5 \$		\$	925	\$	164	\$	1,071	\$	3,414	\$	12,501	\$	_	\$	_	\$	26,830	\$	_	\$	_

<sup>(1)</sup> The most recent monthly base rent (including additional rent floors), cash income from direct financing leases and/or interest income annualized for 12 months. For additional details regarding "annualized revenues," see reporting definitions.

# See Reporting Definitions and Reconciliations of Non-GAAP Measures



<sup>(2)</sup> Includes month-to-month and holdover leases.

Effective January 1, 2011, a senior secured loan to Delphis was placed on non-accrual status. During the nine months ended September 30, 2012, no revenues were recognized for this loan; consequently, no annualized revenue amounts for this loan are presented. For additional information regarding the senior secured loan to Delphis see Note 7 to the Consolidated Financial Statements for the quarter ended September 30, 2012 included in the Company's Quarterly Report on Form 10-Q filed with the SEC.

### **Owned Senior Housing Portfolio**

As of and for the nine months ended September 30, 2012, dollars in thousands

#### Investments

Operating	Property				Average		Occupancy		EBITDA	.R		EBITDAI	RM
Leases	Count	Investment		NOI	Age (Years)	Units	%		Amount	CFC		Amount	CFC
Assisted living	162	\$ 2,482,766	\$	171,133	14	14,598	85.3	\$	226,421	1.11 x	\$	270,132	1.32 x
Independent living	24	516,825		37,414	23	4,126	85.5		51,093	1.08 x		58,585	1.23 x
CCRCs	12	608,655		42,208	22	3,780	87.5		61,066	1.13 x	_	74,377	1.37 x
	198	\$ 3,608,246	\$	250,755	16	22,504	85.7	\$	338,580	1.11 x	\$	403,094	1.32 x
Direct Financing Leases	Property Count	Investment		NOI	Average Age (Years)	Units	Occupancy %	_	EBITDA	CFC	_	EBITDAR Amount	M <sup>(1)</sup>
Assisted living	27	\$ 624,332	<u> </u>	36,914	15	3,138	85.6	<u>-</u>	49,533	1.19 x	_	62,921	1.51 x
HCR ManorCare(1)	66	838,370	Ф	52,912	17	4,953	83.2	φ	47,333 N/A	N/A	Þ	02,921 N/A	N/A
rick Marior Care	93		_		16		84.2		IN/A	11/1		IN/A	IN/A
		\$ 1,462,702	<del>D</del>	89,826	10	8,091	04.2						
Leased Properties	291	\$ 5,070,948	\$	340,581	16	30,595	85.3	\$	388,113	1.12 x	\$	466,015	1.34 x
Operating Properties (RIDEA)	Property Count	Investment		NOI	Average Age (Years)	Units	Occupancy %						
Assisted living	3	\$ 23,707	\$	1,667	22	213	85.1						
Independent living	18	728,884		37,586	22	4,795	86.2						
	21	\$ 752,591	\$	39,253	22	5,008	86.1						
Debt Investments		Investment		Interest Income									
Assisted living <sup>(2)</sup>		\$ 49,237	\$	1,686									
Total	312	\$ 5,872,776	\$	381,520		35,603	85.4						

#### Operator Concentration(3)

	Pro	perties	Investme	ent	NOI a Interest Ir			Occupancy	EBITDAR	EBITDARM
Operator	Count	% Pooled	Amount	%	Amount	%	Units	<u> </u>	CFC <sup>(1)</sup>	CFC <sup>(1)</sup>
Brookdale Senior Living <sup>(4)</sup>	57	60	\$ 1,573,161	27	\$ 103,006	27	11,072	87.1	1.20 x	1.44 x
Sunrise Senior Living <sup>(5)</sup>	48	98	1,324,891	23	70,498	18	5,566	87.0	1.18 x	1.46 x
Emeritus Corporation	69	96	1,143,830	19	93,432	24	7,742	84.4	1.13 x	1.34 x
HCR ManorCare <sup>(1)</sup>	66	100	838,370	14	52,912	14	4,953	83.2	N/A	N/A
Harbor Retirement Associates	14	100	211,164	4	12,088	3	1,345	85.5	0.97 x	1.22 x
Aegis Senior Living	10	80	182,152	3	11,803	3	701	87.0	1.03 x	1.21 x
Other	48	98	599,208	10	37,781	11	4,224	85.6	1.01 x	1.19 x
	312	90	\$ 5,872,776	100	\$ 381,520	100	35,603	85.4	1.12 x	1.34 x





<sup>(1)</sup> EBITDAR, EBITDARM and their respective CFC are not presented for the disaggregated HCR ManorCare senior housing and post-acute/skilled nursing portfolios as the combined portfolio is cross-collateralized under a single master lease. See HCR ManorCare Leased Portfolio Summary on page 19 of this report.
(2) During the quarter ended September 30, 2012, the Company funded \$16.4 million related to construction financing commitments totaling \$119 million to build six Class A assisted living facilities. For each of these facilities, the Company holds a one-time purchase option upon the earlier of stabilized occupancy or the fourth anniversary of the loan closing.
(3) Property count, units, occupancy and CFCs are presented for leased and operating properties, if applicable, and exclude debt investments.

<sup>(4)</sup> Occupancy for 35 assets (formerly operated by Horizon Bay Retirement Living prior to September 2011) and the CFC for 14 of these 35 assets are reported in "other" until the requisite periods have elapsed to allow the Company to report such measures completely under the new operator. CFC for the remaining 21 assets operated under a RIDEA structure is excluded as CFC is not applicable.

(5) Sunrise Senior Living's percentage pooled consists of 47 assets under 6 separate pools.

Dollars in thousands

#### **Portfolio Trends**

				Same Pi	rop	erty Leased			Total	Pro	perty Portfo	olio <sup>(</sup>	1)			
								As of an	d fo	or the						
		As of and	l fo	r the Quarte	er E	nded <sup>(1)</sup>		YTD Perio	od I	nded		As of and fo	r the	Twelve Me	onth	s Ended
	_0	9/30/12	_(	06/30/12	_(	09/30/11	_(	09/30/12		9/30/11	<u>_</u>	9/30/12	06	5/30/12 <sup>(2)</sup>	09	9/30/11(2)
Property count		291		291		291		221		221		312		314		317
Investment	\$ 5	5,067,088	\$	5,057,689	\$	5,008,124	\$	4,133,640	\$	4,094,208	\$	5,823,539	\$ :	5,920,323	\$	5,907,944
Units		30,595		30,588		30,591		25,081		25,087		35,603		36,156		36,418
3-Month Occupancy %		85.3		85.5		84.9		85.6		85.2		85.3		85.5		85.5
12-Month Occupancy %		85.3		85.2		85.5		85.6		85.9		85.4		85.6		86.1
EBITDAR	\$	388,113	\$	389,304	\$	385,694	\$	379,671	\$	376,669	\$	388,113	\$	398,445	\$	402,972
EBITDAR CFC		1.12 x		1.13 x		1.17 x		1.12 x		1.18 x		1.12 x		1.13 x		1.18 x
EBITDARM	\$	466,015	\$	466,898	\$	462,345	\$	456,039	\$	451,875	\$	466,015	\$	477,227	\$	481,409
EBITDARM CFC		1.34 x		1.36 x		1.40 x		1.34 x		1.41 x		1.34 x		1.35 x		1.41 x
NOI: Rental and related revenues	\$	84,775	\$	83,725	\$	83,364	\$	246,515	\$	246,330						
DFL income		29,985		29,859		30,652		36,965		40,175						
Operating expenses		(151)	)	(79)		(179)		(367)		(724)						
	\$	114,609	\$	113,505	\$	113,837	\$	283,113	\$	285,781						
Adjusted NOI:																
Straight-line rents		(6,976)	)	(6,789)		(8,948)		(20,941)		(27,974)						
DFL interest accretion Below market lease		(5,121)	)	(4,436)		(4,498)		(5,774)		(6,506)						
intangibles, net		(358)	_	(358)		(358)	_	(1,177)		(1,177)						
	\$	102,154	\$	101,922	\$	100,033	\$	255,221	\$	250,124						



See Reporting Definitions and Reconciliations of Non-GAAP Measures

<sup>(1)</sup> EBITDAR, EBITDARM and their respective CFC are not presented for the disaggregated HCR ManorCare senior housing and post-acute/skilled nursing portfolios as the combined portfolio is cross-collateralized under a single master lease. See HCR ManorCare Leased Portfolio Summary on page 19 of this report. Additionally, EBITDAR, EBITDARM and their respective CFC are not presented for the 21 properties operated under a RIDEA structure.

(2) Amounts are presented without giving effect to discontinued operations.

# Owned Post-Acute/Skilled Nursing Portfolio

As of and for the nine months ended September 30, 2012, dollars in thousands

#### Investments

Leased	Property			Average Age		Occupancy	EBITD	AR	EBITDA	\RM
Properties	Count	Investment	NOI	(Years)	<u>Beds</u>	%	Amount	CFC	Amount	CFC
Operating leases	45	\$ 247,668 \$	28,728	28	5,300	84.7	\$ 55,698	1.49 x	\$ 75,716	2.02 x
HCR ManorCare DFLs <sup>(1)</sup>	268	5,395,435	374,926	34	36,431	86.0	N/A	N/A	N/A	N/A
Leased properties	313	\$ 5,643,103 \$	403,654	33	41,731	85.9				

Debt Investments	_1	nvestment		Interest Income
Four Seasons Health Care <sup>(2)</sup>	\$	221,018	\$	6,873
Tandem/LaVie <sup>(3)</sup>		98,016		2,133
Other		9,536	_	836
		328,570	_	9,842
Total	\$	5,971,673	\$	413,496

#### Operator Concentration<sup>(4)</sup>

						NOI and					
	Pro <sub>l</sub>	perties		Investmer	<u>nt</u>	Interest Inco	me		Occupancy	EBITDAR	EBITDARM
<u>Operator</u>	Count	% Pooled	_	Amount	<u>%</u>	 Amount	%	Beds	%	CFC <sup>(1)</sup>	CFC <sup>(1)</sup>
HCR ManorCare <sup>(1)</sup>	268	100	\$	5,395,435	90	\$ 374,926	91	36,431	86.0	N/A	N/A
Four Seasons Health Care <sup>(2)</sup>	_	_		221,018	4	6,873	2	_	_	N/A	N/A
Tandem/LaVie <sup>(3)</sup>	9	100		161,116	3	7,273	2	934	94.3	1.89 x	2.39 x
Covenant Care	12	100		65,248	1	7,974	2	1,328	85.3	1.66 x	2.22 x
Kindred Healthcare	9	100		38,117	1	6,273	2	1,288	83.5	0.92 x	1.52 x
Other	15	73		90,739	1	10,177	1	1,750	80.2	1.51 x	2.00 x
	313	99	\$	5,971,673	100	\$ 413,496	100	41,731	85.9	1.49 x	2.02 x

Property count, beds, occupancy and CFCs are presented for leased properties and exclude debt investments.





<sup>(1)</sup> EBITDAR, EBITDARM and their respective CFC are not presented for the disaggregated HCR ManorCare senior housing and post-acute/skilled nursing portfolios as the combined portfolio is cross-

collateralized under a single master lease. See HCR ManorCare Leased Portfolio Summary on page 19 of this report.

(2) On June 28, 2012, the Company purchased senior unsecured notes of Four Seasons Health Care with an aggregate par value of £138.5 million at a discount for £136.8 million. The amount represents the carrying value translated into U.S. dollars as of September 30, 2012. For additional information see Note 10 to the Consolidated Financial Statements for the nine months ended September 30, 2012 included in the Company's Quarterly Report on Form 10-Q filed with the SEC.

On July 31, 2012, the Company funded a \$100 million mezzanine loan to Tandem Health Care. The loan is subordinate to \$400 million in senior mortgage debt and \$137 million in senior mezzanine debt and bears interest at a fixed rate of 12% and an effective rate of 12.4% including loan fees. The Company expects to fund an additional \$105 million between March 2013 and August 2013 that will be used to pay down debt senior to HCP's loan and will bear interest at a fixed rate of 14%. The investments mature October 2017.

# Owned Post-Acute/Skilled Nursing Portfolio

Dollars in thousands, except HCR ManorCare information

#### **Portfolio Trends**

				Same Pr	оре	erty Leased			Tota	ıl L	eased Portfo	lio <sup>(1</sup>	)			
		As of and	for	the Quarte	r Er	nded <sup>(1)</sup>		As of an YTD Peri			ļ _,	As of and fo	r t	he Twelve M	ontl	ns Ended
	0	9/30/12	_0	6/30/12		9/30/11	_	09/30/12	_	09/30/11	=	09/30/12	(	06/30/12(2)	09	P/30/11 <sup>(2)</sup>
Property count		313		313		313		45		45		313		313		313
Investment	\$ :	5,643,103	\$	5,610,791	\$	5,512,400	\$	247,668	\$	244,738	\$	5,643,103	\$	5,610,791	\$	5,512,400
Beds		41,731		41,605		41,773		5,300		5,286		41,731		41,605		41,773
3-Month Occupancy %		85.4		85.9		87.1		84.4		85.5		85.4		85.9		87.1
12-Month Occupancy %		85.9		86.3		87.4		84.7		85.4		85.9		86.3		87.4
EBITDAR	\$	55,698	\$	58,460	\$	64,805	\$	55,698	\$	64,805	\$	55,698	\$	58,460	\$	64,805
EBITDAR CFC		1.49 x		1.58 x		1.78 x		1.49 x		1.78 x		1.49 x		1.58 x		1.78 x
EBITDARM	\$	75,716	\$	78,773	\$	84,856	\$	75,716	\$	84,856	\$	75,716	\$	78,773	\$	84,856
EBITDARM CFC		2.02 x		2.12 x		2.32 x		2.02 x		2.32 x		2.02 x		2.12 x		2.32 x
Quality Mix		64.5%		65.4%		65.4%		64.5%		65.4%		64.5%		65.4%		65.4%
NOI:																
Rental revenues	\$	9,659	\$	9,560	\$	9,548	\$	28,835	\$	28,495						
DFL income		125,849		125,117		122,844		_		_						
Operating expenses		(154)		(170)		(239)		(103		(69						
		135,354		134,507		132,153		28,732		28,426						
Adjusted NOI:																
Straight-line rents		(155)		(102)		(206)		(422)		(792						
DFL interest accretion Above market lease		(18,312)		(17,581)		(19,073)		_		_						
intangibles, net		11		11		11										
	\$	116,898	\$	116,835	\$	112,885	\$	28,310	\$	27,634						

#### **HCR ManorCare Leased Portfolio Summary**

As of and for the nine months ended September 30, 2012, dollars in thousands

Investment	Property			Adjusted		Facility EB	ITDAR	Facility EBI	TDARM
Summary	Count	Investment <sup>(3)</sup>	NOI <sup>(4)</sup>	NOI	Occupancy	Amount	CFC	Amount	CFC
Assisted living	66	\$ 838,370	\$ 52,912	\$ 44,082	83.2%	N/A	N/A	N/A	N/A
Post-acute/skilled	268	5,395,435	374,926	318,594	86.0%	N/A	N/A	N/A	N/A
Total	334	\$ 6,233,805	\$ 427,838	\$ 362,676	85.7%	\$ 497,904	1.04 x	\$ 670,710	1.41 x
	09/30/12	06/30/12	09/30/11						
Quality mix	69.1% <sup>(5)</sup>	69.9%	70.8%						

HCR ManorCare OpCo (guarantor) fixed charge coverage(6)

1.29 x

<sup>(6)</sup> HCR ManorCare OpCo (guarantor) fixed charge coverage is based on EBITDAR for the trailing 12 months, is one quarter in arrears from the date presented and includes home health and hospice EBITDAR and corporate general and administrative expenses, excluding HCR ManorCare's non-recurring expenses associated with the sale of its real estate to HCP. The fixed charges include cash rent and cash interest expense based on the trailing 12 months and are one quarter in arrears from the date presented.





<sup>(1)</sup> EBITDAR, EBITDARM, their respective CFC and quality mix are not presented for the disaggregated HCR ManorCare senior housing and post-acute/skilled nursing portfolios as the combined portfolio is cross-collateralized under a single master lease. For additional information see HCR ManorCare Leased Portfolio Summary.

<sup>(2)</sup> Amounts are presented as originally reported, without giving effect to discontinued operations.

The Company's total investment in HCR ManorCare includes aggregated accumulated DFL accretion of \$216.8 million as of September 30, 2012.

Assisted living and post-acute/skilled nursing NOI includes reductions of \$5.5 million and \$38.9 million, respectively, related to HCP's equity interest in HCR ManorCare OpCo.

<sup>(5)</sup> Private-pay and Medicare revenues as a percentage of total revenues are 31.8% and 37.3% respectively.

# **Owned Life Science Portfolio**

As of and for the nine months ended September 30, 2012, dollars and square feet in thousands

#### Investments

	Property			Average	Square	
Leased Properties	Count	 Investment	NOI	Age (Years)	Feet	Occupancy %
San Francisco	77	\$ 2,628,562	\$ 138,739	19	4,674	89.0
San Diego	21	595,843	28,235	19	1,581	88.1
Other	11	 125,903	10,365	19	746	100.0
	109	\$ 3,350,308	\$ 177,339	19	7,001	90.0

#### **Tenant Concentration**

_	 Annualized Re	venues	Square Fe	et
Tenant	 Amount	%	Amount	%
Amgen	\$ 42,247	18	684	11
Genentech	38,653	17	794	13
Rigel Pharmaceuticals	13,316	6	147	2
Exelixis, Inc.	13,184	6	295	5
Takeda	10,828	5	229	4
LinkedIn Corporation	9,642	4	303	5
Google	8,319	4	270	4
Myriad Genetics	7,217	3	310	5
General Atomics	5,789	3	281	4
ARUP	5,418	2	324	5
Other	 76,234	32	2,663	42
	\$ 230,847	100	6,300	100

#### **Portfolio Trends**

	Same Property Leased Portfolio									Total Leased Portfolio					
	As of and for the Quarter Ended							As of and YTD Perio			At	the Period End	ed		
	_0	9/30/12	_	06/30/12	_	09/30/11	_	09/30/12	_(	09/30/11	09/30/12	06/30/12(1)	09/30/11(1)		
Property count		101		101		101		101		101	109	109	104		
Investment	\$ :	3,215,177	\$	3,207,732	\$	3,206,873	\$	3,215,177	\$	3,206,873	\$ 3,350,308	\$ 3,340,155	\$ 3,263,062		
Square feet		6,685		6,685		6,685		6,685		6,685	7,001	7,000	6,798		
Occupancy %		91.4		91.5		91.1		91.4		91.1	90.0	89.6	90.0		
NOI: Rental and related revenues	\$	60,940	\$	60,697	\$	60,282	\$	182,467	\$	182,602					
Tenant recoveries		9,344		11,016		10,431		30,639		30,979					
Operating expenses		(10,422	)	(12,351)	(	(12,358)		(34,460)		(35,980)					
	\$	59,862	\$	59,362	\$	58,355	\$	178,646	\$	177,601					
Adjusted NOI:															
Straight-line rents Above (below) market	ŀ	(2,790)	)	(3,081)	)	(3,101)		(5,530)		(11,024)					
lease intangibles, ne Lease termination		135		128		(341)		352		(722)					
fees		(175			_	(1,589)	_	(175 <sub>)</sub>	_	(4,767)					
	\$	57,032	\$	56,409	\$	53,324	\$	173,293	\$	161,088					

<sup>(1)</sup> Amounts are presented as originally reported, without giving effect to discontinued operations.





20

# **Owned Life Science Portfolio**

Dollars and square feet in thousands, except dollars per square foot

### Selected Lease Expirations Data (next 3 years):

		To	otal			San Fr	cisco	San I	JO	Other				
	Square I	Feet	Ar	nnualized F	Revenues	Square	Α	nnualized	Square	Ar	nualized	Square	An	nualized
Year	Amount	%	_	Amount	%	Feet	_1	Revenues	Feet	Revenues		Feet	Revenues	
2012(1)	43	1	\$	166	_	43	\$	166	_	\$	_	_	\$	_
2013	437	7		11,238	5	315		9,145	45		1,407	77		686
2014	342	5		10,244	4	215		6,666	127		3,578	_		_
Thereafter	5,478	87		209,199	91	3,589		157,860	1,220		38,205	669		13,134
	6,300	100	\$	230,847	100	4,162	\$	173,837	1,392	\$	43,190	746	\$	13,820

Leasing Activity	Leased Square Feet	Base I	ualized Rent Per re Foot	% Change In Rents	•	enant ements are Foot	Co	asing sts Per are Foot	Average Lease Term (Months)	Retention Rate YTD
Leased Square Feet as of December 31, 2011	6,113	\$	36.24							
Redevelopments placed in service	54		27.68							
Expirations	(194)		31.44							
Renewals, amendments and extensions	160		28.45	(9.0)	\$	5.63	\$	9.38	110	82.3
New leases and expansions	75		29.39			18.91		7.90	67	
Terminations	(41)		33.84							
Leased Square Feet as of March 31, 2012	6,167	\$	36.74							
Acquisitions	77		9.79							
Expirations	(83)		21.13							
Renewals, amendments and extensions	65		23.91	0.1	\$	_	\$	1.12	20	81.1
New leases and expansions	48		11.82			_		1.92	81	
Leased Square Feet as of June 30, 2012	6,274	\$	36.62							
Expirations	(358)		21.99							
Renewals, amendments and extensions	348		18.44	(15.1)	\$	0.58	\$	1.75	119	90.2
New leases and expansions	57		26.48			39.53		10.80	67	
Terminations	(21)		25.08							
Leased Square Feet as of September 30, 2012	6,300	\$	36.64							

<sup>(1)</sup> Includes month-to-month and holdover leases.



# **Owned Medical Office Portfolio**

As of and for the nine months ended September 30, 2012, dollars and square feet in thousands

#### Investments

	Property			Average		
Leased Properties	Count	Investment	NOI	Age (Years)	Square Feet	Occupancy %
On-Campus	156	\$ 2,044,516	\$ 119,711	19	11,673	91.2
Off-Campus	48	492,067	 28,319	19	2,366	92.9
	204	\$ 2,536,583	\$ 148,030	19	14,039	91.5

#### **Portfolio Trends**

				Same P	rop	erty Leased		Total Leased Portfolio					
		As of an	d fo	or the Quart	er	Ended		As of an YTD Peri			At	the Period End	ed
	0	9/30/12	_(	06/30/12		09/30/11	_(	09/30/12	_(	09/30/11	09/30/12	06/30/12(1)	<b>09/30/11</b> <sup>(1)</sup>
Property count		184		184		184		183		183	204	185	188
Investment	\$ 2	2,292,882	\$	2,282,122	\$	2,253,279	\$	2,261,060	\$	2,221,711	\$ 2,536,583	\$ 2,295,609	\$ 2,285,159
Square feet		12,880		12,885		12,849		12,747		12,717	14,039	12,972	13,104
Occupancy %		91.8		91.6		90.9		91.8		90.8	91.5	91.4	91.0
NOI: Rental and related revenues	\$	68,496	\$	68,813	\$	67,179	\$	202,937	\$	199,242			
Tenant recoveries		12,931		11,801		12,713		35,175		35,658			
Operating expenses		(31,752		(30,442)		(31,409)		(90,927)		(90,801)			
	\$	49,675	\$	50,172	\$	48,483	\$	147,185	\$	144,099			
Adjusted NOI:													
Straight-line rents Above market lease		(980)	)	(1,039)		(1,095)		(3,236)		(4,581)			
intangibles, net		101		83		91		258		274			
Lease termination fees				(251)				(251)					
	\$	48,796	\$	48,965	\$	47,479	\$	143,956	\$	139,792			

<sup>(1)</sup> Amounts are presented as originally reported, without giving effect to discontinued operations.



#### **Owned Medical Office Portfolio**

Square feet in thousands Leasing Activity Leased **Annualized** % **HCP Tenant** Leasing Retention Average Change **Costs Per** Square **Base Rent Per Improvements** Lease Term Rate In Rents(1) Feet Per Square Foot Square Foot (Months) YTD Square Foot 12,001 Leased Square Feet as of December 31, 2011 22.13 \$ Dispositions/redevelopment 15.59 (143)**Expirations** (462)22.81 0.8 2.55 58 81.4 Renewals, amendments and extensions 376 23.16 12.64 New leases 64 19.75 14.38 3.63 50 **Terminations** (23)21.31 Leased Square Feet as of March 31, 2012 11,813 22.41 Redevelopment (37)17.50 **Expirations** (449)22.32 0.5 \$ 50 78.4 Renewals, amendments and extensions 338 22.39 8.55 \$ 2.77 New leases 214 18.46 18.87 3.25 57 **Terminations** 20.68 (20)Leased Square Feet as of June 30, 2012 11,859 22.50 968 22.01 Acquisitions/redevelopment **Expirations** (535)23.96 Renewals, amendments and extensions 418 23.06 0.7 5.97 \$ 2.49 66 78.3 New leases 197 21.80 20.63 7.00 76 **Terminations** (59) 21.27 Leased Square Feet as of September 30, 2012 12,848 22.56

<sup>(1)</sup> For comparative purposes, the calculation reflects adjustments for leases that converted to a different lease type upon renewal, amendment or extension of the original lease.





# **Owned Hospital Portfolio**

As of and for the nine months ended September 30, 2012, dollars in thousands

#### Investments

Leased	Property				Average		Occupancy		EBITDA	R <sup>(1)</sup>	EBITDAR	M <sup>(1)</sup>
<b>Properties</b>	Count	<u>_lr</u>	nvestment	 NOI	Age (Years)	Beds	% <sup>(1)</sup>	_	Amount	CFC	Amount	CFC
Acute care	5	\$	452,674	\$ 43,527	36	1,578	50.2	\$	327,146	5.56 x	\$ 353,591	6.01 x
Rehab	7		98,526	7,087	22	520	60.0		29,005	3.22 x	33,170	3.68 x
Specialty	2		63,725	3,788	29	68	_		18,900	3.63 x	20,835	4.00 x
LTACH	3		35,205	 6,128	18	244	50.0		7,065	0.97 x	10,104	1.38 x
	17	\$	650,130	\$ 60,530	26	2,410	52.8	\$	382,116	4.76 x	\$ 417,700	5.20 x

Debt Investments	<u>lr</u>	nvestment	nterest ncome
Acute care	\$	15,384	\$ 785
Specialty <sup>(2)</sup>		68,755	 _
	\$	84,139	\$ 785
Total	\$	734,269	\$ 61,315

### Operator Concentration(3)

	Proj	perties	Investme	ent	NOI ar Interest Inc		
Operator <sup>(1)</sup>	Count	% Pooled	Amount	%	Amount	%	Beds
Tenet Healthcare	3	_	\$ 196,709	27	\$ 17,403	28	756
HCA	1	_	167,165	23	15,912	26	668
Delphis	2	_	132,480	18	3,787	6	68
Hoag Memorial Hospital Presbyterian	1	_	88,800	12	10,219	17	154
Other	10	70	149,115	20	13,994	23	764
	17	41	\$ 734,269	100	\$ 61,315	100	2,410

Property count and beds are presented for leased properties and exclude debt investments.





24

<sup>(1)</sup> Certain operators in HCP's hospital portfolio are not required under their respective leases to provide operational data.
(2) Represents a senior secured loan to Delphis that was placed on non-accrual status effective January 1, 2011. For additional information regarding the senior secured loan to Delphis see Note 7 to the Consolidated Financial Statements for the quarter ended September 30, 2012 included in the Company's Quarterly Report on Form 10-Q filed with the SEC.

# **Owned Hospital Portfolio**

Dollars in thousands

#### **Portfolio Trends**

				Same Pr	оре	erty Leased	ed Portfolio					Total Leased Portfolio					
		As of an	d fo	r the Quart	er E	inded		As of an YTD Peri				s of and fo	r th	e Twelve M	ontl	ns Ended	
	0	9/30/12	_(	06/30/12	_(	9/30/11	0	9/30/12	_	09/30/11	<u> </u>	9/30/12	0	6/30/12 <sup>(1)</sup>	09	9/30/11(1)	
Property count		16		16		16		16		16		17		17		17	
Investment	\$	610,385	\$	608,463	\$	608,641	\$	610,385	\$	608,641	\$	650,130	\$	648,208	\$	648,386	
Beds		2,379		2,379		2,379		2,379		2,379		2,410		2,410		2,379	
3-Month Occupancy %		54.3		56.3		53.1		54.3		53.1		54.3		56.3		53.1	
12-Month Occupancy %		52.8		52.6		52.6		52.8		52.6		52.8		52.6		52.6	
EBITDAR	\$	373,340	\$	364,098	\$	311,906	\$	373,340	\$	311,906	\$	382,116	\$	373,339	\$	321,040	
EBITDAR CFC		4.83 x		4.73 x		4.08 x		4.83 x		4.08 x		4.76 x		4.67 x		4.05 x	
EBITDARM	\$	407,965	\$	398,473	\$	344,912	\$	407,965	\$	344,912	\$	417,700	\$	408,748	\$	355,405	
EBITDARM CFC		5.27 x		5.18 x		4.51 x		5.27 x		4.51 x		5.20 x		5.12 x		4.48 x	
NOI:																	
Rental and related			_		_		_		_								
revenues	\$	20,547		21,848		20,091	\$	61,008		59,726							
Operating expenses		(900)	_	(936)	_	(1,226)	_	(2,764)	_	(3,412)							
	\$	19,647	\$	20,912	\$	18,865	\$	58,244	\$	56,314							
Adjusted NOI:																	
Straight-line rents Below market lease		(99)		(161)		(192)		(444)		(720)							
intangibles, net		(193)		(193)		(193)		(578)		(578)							
	\$	19,355	\$	20,558	\$	18,480	\$	57,222	\$	55,016							

<sup>(1)</sup> Amounts are presented as originally reported, without giving effect to discontinued operations.



# **Investment Management Platform**

As of and for the nine months ended September 30, 2012, dollars and square feet in thousands

Unconsolidated Institutional Joint Ventures	Primary Segment	Date Established Acquired		HCP's Ownersh Percenta	nip	Join Ventur Investm	e's	Joint Venture' Mortgag Debt		ty Ma	HCP's vestment nagement e Income	Initial Term (in years)
HCP Ventures III HCP Ventures IV HCP Life Science	Medical office Medical office Life science	October-0 April-07 August-07		30% <sup>(2</sup> 20% 50%-63		\$ 144, 662, 144, \$ 951,	556 481	\$ 91,7 373,4 3,9 \$ 469,1	46 33 36 6	7,774 \$ 3,071 7,263 8,108 \$	290 1,130 3 1,423	10 97-98
Selected Financial L	Data <sup>(3)</sup>			Three A	Mont	hs Ended S	Septe	mber 30, 20	12 Nine M	onths Ended	September	r 30. 2012
						Office		Life Science		cal Office		Science
Total revenues Operating expens NOI Depreciation and General and adm	amortization inistrative			\$		19,049 (8,387) 10,662 (7,346) (660)	\$ \$	2,3 (3	70) 39 \$ 94) (5)	57,850 (24,302) 33,548 (21,513) (2,475)	\$	8,084 (1,071) 7,013 (1,184) (30)
Interest expense of Net income (los Depreciation and	ss)			\$		(7,151) (4,495) 7,346	\$	1,8	( <u>82</u> ) 58 \$ 94	(20,651) (11,091) 21,513	\$	(291) 5,508 1,184
<b>FFO</b> Amortization of al	bove and below m	arket lease		\$		2,851	\$	2,2		10,422	\$	6,692
intangibles, net Amortization of de Straight-line rents Leasing costs and	eferred financing o	,	nts			(182) 214 (179) (2,618)			7 96 —	(552) 566 (741) (6,752)		24 274 (2)
FAD	·	·		\$		86	\$	2,3	55 \$	2,943	\$	6,988
HCP's pro rata sh	are of net income	(loss)		\$		(902)	\$	1,0	87 \$	(2,227)	\$	3,220
HCP's pro rata sh	are of FFO			\$		697	\$	1,3	02 \$	2,456	\$	3,867
HCP's pro rata sh	are of FAD			\$		93	\$	1,3	59 \$	861	\$	4,030
HCP Ventures III		Property Count	<u>In</u>	vestment		NOI		Adjusted NOI	Average Age (Years)	Square Feet	Оссиј	pancy % <sup>(4)</sup>
Medical office:		•	<b>.</b>	100 017	•		· •	. 7.10	10	/10		0/ 0
On-Campus Off-Campus		9 4	\$	109,917 34,127	\$	6,849 1,719		6,740 1,735	12 11	619 183		96.8 91.2
On Campos		13	\$	144,044	\$	8,56		8,475	12	802	<b>-</b> <b>-</b>	95.5
HCP Ventures IV Medical office:												
On-Campus		22	\$	217,940	\$	8,00	5 \$	8,005	23	1,103		75.3
Off-Campus Hospital:		31		363,233		14,66	9	13,782	21	1,487		83.8
LTACH		1		12,193		(1		(11)	6	N/A		N/A
Specialty		<u>3</u> 57	<u>-</u>	69,190	<u>•</u>	2,31		1,964	7	N/A		N/A
		5/	\$	662,556	\$	24,98	1 \$	23,740	21			
HCP Life Science												
San Francisco		2	\$	74,700	\$	3,55		3,808	15	147		100.0
San Diego		2	_	69,781	_	3,45	_	3,479	17	131	_	90.3
		4	\$	144,481	\$	7,013	3 \$	7,287	16	278		95.4
						40,56	_					

<sup>(1)</sup> The carrying value of investments in unconsolidated joint ventures is based on the amount the Company paid to purchase the joint venture interest, which is different from the Company's capital balance as reflected at the joint venture level as the records of the unconsolidated joint venture are reflected at their historical cost. These differences in basis are generally amortized over the lives of the related assets and liabilities and included in the Company's share of equity in earnings of the respective joint venture.





<sup>&</sup>lt;sup>(2)</sup> The Company owns an 85% interest in HCP Birmingham Portfolio LLC, which owns a 30% interest in HCP Ventures III.

General information is combined by primary segment of each joint venture (i.e., HCP Ventures III and HCP Ventures IV are combined under the medical office column).
 General information is combined by primary segment of each joint venture (i.e., HCP Ventures III and HCP Ventures IV are combined under the medical office column).
 Gertain operators in the Investment Management Platform hospital portfolio are not required under their respective leases to provide operational data.

Adjusted Fixed Charge Coverage. Adjusted EBITDA divided by Fixed Charges. The Company uses Adjusted Fixed Charge Coverage, a non-GAAP financial measure, as a measure of liquidity. The Company believes Adjusted Fixed Charge Coverage provides investors, particularly fixed income investors, relevant and useful information because it measures the Company's ability to meet its interest payments on outstanding debt and pay dividends to its preferred stockholders. The Company's various debt agreements contain covenants that require the Company to maintain ratios similar to Adjusted Fixed Charge Coverage, and credit rating agencies utilize similar ratios in evaluating and determining the credit rating on certain debt instruments of the Company. However, since this ratio is derived from Adjusted EBITDA and Fixed Charges, its usefulness is limited by the same factors that limit the usefulness of Adjusted EBITDA and Fixed Charges. Further, the Company's computation of Adjusted Fixed Charge Coverage may not be comparable to similar fixed charge coverage ratios reported by other companies. The Company has provided reconciliations of this measure to the most comparable GAAP measure in this supplemental information package and for certain historical trend information on page 6, such reconciliations are available in the Company's Current Reports on Form 8-K filed with the SEC dated February 14, 2012 (2011 metrics), February 15, 2011 (2010 metrics), February 12, 2010 (2009 metrics), February 10, 2009 (2008 metrics), February 11, 2008 (2008 and 2007 metrics) and July 30, 2007 (Pre-CNL Acquisition metrics).

The following table details the calculation of Adjusted Fixed Charge Coverage (dollars in thousands):

		Inree Moi Septen				Nine Mor Septem		
	_	2012	_	2011	_	2012	_	2011
Adjusted EBITDA	\$	405,622	\$	384,828	\$	1,195,684	\$	1,086,662
Interest expense:								
Continuing operations	\$	103,513	\$	103,459	\$	309,875	\$	315,695
Discontinued operations		505		739		1,936		2,208
HCP's share of interest expense from the Investment Management Platform		1,622		1,584		4,728		4,743
Capitalized interest		5,022		6,857		18,517		19,395
Preferred stock dividends		_		5,282		6,574		15,848
Fixed charges	\$	110,662	\$	117,921	\$	341,630	\$	357,889
Adjusted fixed charge coverage		3.7x		3.3x		3.5x		3.0x

Annualized Revenues. The most recent month's (or subsequent month's if acquired in the most recent month) base rent including additional rent floors, cash income from direct financing leases and/or interest income annualized for 12 months. Annualized Revenues for operating properties under a RIDEA structure are calculated based on the most recent quarter's NOI annualized for 12 months. Annualized Revenues do not include tenant recoveries, additional rents in excess of floors and non-cash revenue adjustments (i.e., straight-line rents, amortization of above and below market lease intangibles, DFL interest accretion and deferred revenues). The Company uses Annualized Revenues for the purpose of determining Operator/Tenant Diversification, Lease Expirations and Debt Investment Maturities. Annualized revenues for properties classified as held for sale are excluded.

Assets Held for Sale. Assets of discontinued operations in accordance with Accounting Standards Codification Topic 360.

Assisted Living Facility ("ALF"). A senior housing facility that predominantly consists of assisted living units is classified by the Company as an ALF.

Cash Flow Coverage ("CFC"). Facility EBITDAR or Facility EBITDARM for the trailing 12 months and one quarter in arrears from the date reported divided by the Same Period Rent. Cash Flow Coverage is a supplemental measure of a property's ability to generate cash flows for the operator/tenant (not the Company) to meet the operator's/tenant's related rent and other obligations to the Company. However, its usefulness is limited by, among other things, the same factors that limit the usefulness of Facility EBITDAR or Facility EBITDARM. The coverages shown exclude newly completed facilities under start-up, vacant facilities and facilities for which data is not available or meaningful.

Consolidated Assets. Total assets as reported in the Company's consolidated financial statements.

Consolidated Debt. The carrying amount of bank line of credit, bridge and term loans (if applicable), senior unsecured notes, mortgage and other secured debt, and other debt as reported in the Company's consolidated financial statements.

Consolidated Gross Assets. The carrying amount of total assets, excluding investments in and advances to unconsolidated joint ventures, after adding back accumulated depreciation and amortization, as reported in the Company's consolidated financial statements.

Consolidated Secured Debt. Mortgage and other debt secured by real estate, excluding debt on assets held for sale as reported in the Company's consolidated financial statements.

Continuing Care Retirement Community ("CCRC"). A senior housing facility which provides at least three levels of care (i.e., independent living, assisted living and skilled nursing) is classified by the Company as a CCRC.

**Debt Investments.** Loans secured by a direct interest in real estate and mezzanine loans.

**Development.** Includes ground-up construction and redevelopments.

Direct Financing Lease ("DFL"). The Company uses the direct finance method of accounting to record income from DFLs. For leases accounted for as DFLs, future minimum lease payments are recorded as a receivable. The difference between the future minimum lease payments and the estimated residual values less the cost of the properties is recorded as unearned income. Unearned income is deferred and amortized to income over the lease terms to provide a constant yield.

Estimated Completion Date. For development projects, management's estimate of the date the core and shell structure improvements are expected to be or have been completed. For redevelopment projects, management's estimate of the time in which major construction activity in relation to the scope of the project has been substantially completed.



Nine Mentles Ended

EBITDA and Adjusted EBITDA. The real estate industry uses earnings before interest, taxes, depreciation and amortization ("EBITDA"), a non-GAAP financial measure, as a measure of both operating performance and liquidity. Adjusted EBITDA is calculated as EBITDA excluding impairments, gains or losses from real estate dispositions, and litigation settlement charge. The Company uses EBITDA and Adjusted EBITDA to measure both its operating performance and liquidity. The Company considers Adjusted EBITDA to provide investors relevant and useful information because it permits investors to view income from its operations on an unleveraged basis before the effects of taxes, non-cash depreciation and amortization, impairments, impairment recoveries, and gains or losses from real estate dispositions. By excluding interest expense, Adjusted EBITDA allows investors to measure the Company's operating performance independent of its capital structure and indebtedness and, therefore, allows for a more meaningful comparison of its operating performance between quarters as well as annual periods and to compare its operating performance to that of other companies, both in the real estate industry and in other industries. As a liquidity measure, the Company believes that EBITDA and Adjusted EBITDA help investors analyze the Company's ability to meet its interest payments on outstanding debt and to make preferred dividend payments. The Company believes investors should consider EBITDA and Adjusted EBITDA, in conjunction with net income (the primary measure of the Company's performance) and the other required GAAP measures of its performance and liquidity, to improve their understanding of the Company's operating results and liquidity, and to make more meaningful comparisons of its performance between periods and against other companies. EBITDA and Adjusted EBITDA have limitations as analytical tools and should be used in conjunction with the Company's required GAAP presentations. EBITDA and Adjusted EBITDA do not reflect the Company's historical cash expenditures or future cash requirements for capital expenditures or contractual commitments. While Adjusted EBITDA is a relevant and widely used measure of operating performance and liquidity, it does not represent net income or cash flow from operations as defined by GAAP, and it should not be considered as an alternative to those indicators in evaluating operating performance or liquidity. Further, the Company's computation of EBITDA and Adjusted EBITDA may not be comparable to similar measures reported by other companies.

Thurs Mandha Endad

Nima Mantha Endad

The following table reconciles Adjusted EBITDA from net income (in thousands):

	Three Mor Septem	 	 Nine Mon Septem		
	2012	 2011	2012	_	2011
Net income	\$ 199,043	\$ 175,471	\$ 600,582	\$	483,707
Interest expense:					
Continuing operations	103,513	103,459	309,875		315,695
Discontinued operations	505	739	1,936		2,208
Income taxes:					
Continuing operations	(598)	5	(1,131)		289
Discontinued operations	(103)	_	_		1
Depreciation and amortization of real estate, in-place lease and other intangibles:					
Continuing operations	88,686	86,672	259,039		265,742
Discontinued operations	1,453	1,884	7,300		4,286
Equity income from unconsolidated joint ventures	(13,396)	(17,050)	(42,803)		(32,798)
HCP's share of EBITDA from the Investment Management Platform	3,619	3,767	11,051		11,736
Other joint venture adjustments	 15,022	14,481	 44,813		28,165
EBITDA	\$ 397,744	\$ 369,428	\$ 1,190,662	\$	1,079,031
Gain on sales of real estate	_	_	(2,856)		_
Impairments	7,878	15,400	7,878		15,400
Gain upon consolidation of joint venture	_	_	_		(7,769)
Adjusted EBITDA	\$ 405,622	\$ 384,828	\$ 1,195,684	\$	1,086,662

Facility EBITDAR ("EBITDAR"). Earnings before interest, taxes, depreciation, amortization and rent for a particular facility accruing to the operator/tenant of the property (not the Company), for the trailing 12 months and one quarter in arrears from the date reported. The Company uses Facility EBITDAR in determining Cash Flow Coverage. Facility EBITDAR has limitations as an analytical tool. Facility EBITDAR does not reflect historical cash expenditures or future cash requirements for facility capital expenditures or contractual commitments. In addition, Facility EBITDAR does not represent a property's net income or cash flow from operations and should not be considered an alternative to those indicators. However, the Company receives periodic financial information from operators/tenants regarding the performance of the Company's facilities under the operator's/tenant's management. The Company utilizes Facility EBITDAR as a supplemental measure of the ability of those properties to generate sufficient liquidity to meet related obligations to the Company. Facility EBITDAR includes the greater of (i) contractual management fees or (ii) an imputed management fee of 5% for senior housing facilities and post-acute/skilled nursing facilities and 2% for acute care hospitals which the Company believes represents typical management fees in their respective industries. All facility financial performance data was derived solely from information provided by operators/tenants and borrowers without independent verification by the Company.

Facility EBITDARM ("EBITDARM"). Earnings before interest, taxes, depreciation, amortization, rent and management fees for a particular facility accruing to the operator/tenant of the property (not the Company), for the trailing 12 months and one quarter in arrears from the date reported. The Company uses Facility EBITDARM in determining Cash Flow Coverage. Facility EBITDARM has limitations as an analytical tool. Facility EBITDARM does not reflect historical cash expenditures or future cash requirements for facility capital expenditures or contractual commitments. In addition, Facility EBITDARM does not represent a property's net income or cash flow from operations and should not be considered an alternative to those indicators. However, the Company receives periodic financial information from operators/tenants regarding the performance of the Company's facilities under the operator's/tenant's management. The Company utilizes Facility EBITDARM as a supplemental measure of the ability of those properties to generate sufficient liquidity to meet related obligations to the Company. All facility financial performance data was derived solely from information provided by operators/tenants and borrowers without independent verification by the Company.



Financial Leverage. Total Debt divided by Total Gross Assets. The Company believes that its Financial Leverage is a meaningful supplemental measure of its financial position, which enables both management and investors to analyze its leverage and to compare its leverage to that of other companies. The Company believes that the ratio of Consolidated Debt to Consolidated Gross Assets is the most directly comparable GAAP measure to Financial Leverage. The Company's computation of its Financial Leverage may not be identical to the computations of financial leverage reported by other companies. The Company's pro rata share of total debt from the Investment Management Platform is not intended to reflect its actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the joint ventures. The Company has provided reconciliations of this measure to the most comparable GAAP measure in this supplemental information package and for certain historical trend information on page 6, such reconciliations are available in the Company's Current Reports on Form 8-K filed with the SEC dated February 14, 2012 (2011 metrics), February 15, 2011 (2010 metrics), February 12, 2010 (2009 metrics), February 10, 2009 (2008 metrics), February 11, 2008 (2008 and 2007 metrics) and July 30, 2007 (Pre-CNL Acquisition metrics).

Fixed Charges. Total interest expense plus capitalized interest plus preferred stock dividends. The Company uses Fixed Charges to measure its interest payments on outstanding debt and dividends to its preferred stockholders for purposes of presenting Fixed Charge Coverage and Adjusted Fixed Charge Coverage. However, the usefulness of Fixed Charges is limited as, among other things, it does not include all contractual obligations. The Company's computation of Fixed Charges should not be considered an alternative to fixed charges as defined by Item 503(d) of Regulation S-K and may not be comparable to fixed charges reported by other companies.

Funds Available for Distribution ("FAD"). Funds Available for Distribution is defined as FFO as adjusted after excluding the impact of the following: (i) amortization of acquired above/below market lease intangibles, net; (ii) amortization of deferred compensation expense; (iii) amortization of deferred financing costs, net; (iv) straight-line rents; (v) accretion and depreciation related to DFLs; and (vi) deferred revenues. Further, FAD is computed after deducting recurring capital expenditures, including leasing costs and second generation tenant and capital improvements, and includes similar adjustments to compute the Company's share of FAD from its unconsolidated joint ventures. Other real estate investment trusts ("REITs") or real estate companies may use different methodologies for calculating FAD, and accordingly, the Company's FAD may not be comparable to those reported by other REITs. Although the Company's FAD computation may not be comparable to that of other REITs, management believes FAD provides a meaningful supplemental measure of the Company's ability to fund its ongoing dividend payments. In addition, management believes that in order to further understand and analyze the Company's liquidity, FAD should be compared with net cash flows from operating activities as determined in accordance with GAAP and presented in its consolidated financial statements. FAD does not represent cash generated from operating activities determined in accordance with GAAP, and FAD should not be considered as an alternative to net income (determined in accordance with GAAP) as an indication of the Company's performance, as an alternative to net cash flows from operating activities (determined in accordance with GAAP), or as a measure of the Company's liquidity.

Funds From Operations ("FFO"). The Company believes that net income as defined by GAAP is the most appropriate earnings measure. The Company also believes that Funds From Operations, or FFO, as defined by the National Association of Real Estate Investment Trusts ("NAREIT"), FFO applicable to common shares, Diluted FFO applicable to common shares, and Basic and Diluted FFO per common share are important non-GAAP supplemental measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. However, since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. Thus, NAREIT created FFO as a supplemental measure of operating performance for REIT that excludes historical cost depreciation and amortization, among other items, from net income, as defined by GAAP. FFO is defined as net income (determined in accordance with GAAP), excluding gains or losses from acquisition and dispositions of depreciable real estate or related interests, impairments of, or related to, depreciable real estate, plus real estate and DFL depreciation and amortization, with adjustments to derive the Company's pro rata share of FFO from consolidated and unconsolidated joint ventures. Adjustments for joint ventures are calculated to reflect FFO on the same basis. The Company believes that the use of FFO, combined with the required GAAP presentations, improves the understanding of operating results of REITs among investors and makes comparisons of operating results among such companies more meaningful. The Company considers FFO to be a useful measure for reviewing comparative operating and financial performance because, by excluding gains or losses related to sales of previously depreciated operating real estate assets and real estate and DFL depreciation and amortization, FFO can help investors compare the operating performance of a REIT between periods or as compared to other companies. While FFO is a relevant and widely used measure of operating performance of REITs, it does not represent cash flows from operations or net income as defined by GAAP and should not be considered an alternative to those measures in evaluating the Company's liquidity or operating performance. FFO also does not consider the costs associated with capital expenditures related to the Company's real estate assets, nor is FFO necessarily indicative of cash available to fund the Company's future cash requirements. The Company's computation of FFO may not be comparable to FFO reported by other REITs that do not define the term in accordance with the current NAREIT definition or that interpret the current NAREIT definition differently from the Company. For a reconciliation of FFO to net income, please refer to the slide in this supplemental information package captioned "Consolidated Funds From Operations."

FFO as adjusted represents FFO before the impact of litigation settlement charges, preferred stock redemption charges, impairments (recoveries) of non-depreciable assets and merger-related items. Merger-related items include estimated acquisition pursuit costs that consist primarily of professional fees and the impact of common stock offerings which increase the weighted average shares outstanding, when such proceeds will be used to fund a portion of the cash consideration of the Company's pending acquisitions. Management believes FFO as adjusted is a useful alternative measurement. This measure is a modification of the NAREIT definition of FFO and should not be used as an alternative to net income (determined in accordance with GAAP).

FAD Payout Ratio. Dividends declared per common share divided by Diluted FAD per common share for a given period. The Company believes the FAD Payout Ratio per Common Share provides investors relevant and useful information because it measures the portion of FAD being declared as dividends to common stockholders. FAD Payout Ratio per Common Share is subject to the same limitations noted in the definition of FAD above

FFO Payout Ratio. Dividends declared per common share divided by Diluted FFO per common share for a given period. The Company believes the FFO Payout Ratio per Common Share provides investors relevant and useful information because it measures the portion of FFO being declared as dividends to common stockholders. FFO Payout Ratio per Common Share is subject to the same limitations noted in the definition of FFO above.



HCP Life Science. Includes three unconsolidated joint ventures between the Company and an institutional capital partner for which the Company is the managing member. HCP Life Science includes the following partnerships: (i) Torrey Pines Science Center LP (50%), (ii) Britannia Biotech Gateway LP (55%) and (iii) LASDK LP (63%). The unconsolidated joint ventures were acquired as part of the Company's purchase of Slough Estates USA Inc. on August 1, 2007.

HCP Ventures III. An unconsolidated joint venture formed on October 27, 2006 between the Company and an institutional capital partner, for which the Company is the managing member and has an effective 25.5% interest.

HCP Ventures IV. An unconsolidated joint venture formed on April 30, 2007 between the Company and an institutional capital partner, for which the Company is the managing member and has a 20% interest.

Independent Living Facility ("ILF"). A senior housing facility that predominantly consists of independent living units.

**Investment**. Represents (i) the carrying amount of real estate assets, including intangibles, after adding back accumulated depreciation and amortization, excluding assets held for sale and classified as discontinued operations and (ii) the carrying amount of DFLs and debt investments.

Investment Management Platform. Includes the following unconsolidated joint ventures: (i) HCP Life Science, (ii) HCP Ventures III and (iii) HCP Ventures IV.

Life Science. Laboratory and office space primarily for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry.

Long-Term Acute Care Hospitals ("LTACHs"). LTACHs provide care for patients with complex medical conditions that require longer stays and more intensive care, monitoring or emergency back-up than that available in most skilled nursing-based programs.

Net Operating Income from Continuing Operations ("NOI"). A non-GAAP supplemental financial measure used to evaluate the operating performance of real estate properties and SPP. The Company defines NOI as rental and related revenues, including tenant recoveries, resident fees and services, and income from DFLs, less property level operating expenses. NOI excludes interest income, investment management fee income, interest expense, depreciation and amortization, general and administrative expenses, litigation settlement, impairments, impairment recoveries, other income, net, income taxes, equity income from and impairments of unconsolidated joint ventures, and discontinued operations. The Company believes NOI provides investors relevant and useful information because it reflects only income and operating expense items that are incurred at the property level and presents them on an unleveraged basis. Adjusted NOI is calculated as NOI eliminating the effects of straight-line rents, DFL accretion, amortization of above and below market lease intangibles, and lease termination fees. Adjusted NOI is sometimes referred to as "cash NOI." The Company uses NOI and adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and evaluate SPP. The Company believes that net income is the most directly comparable GAAP measure to NOI. NOI should not be viewed as an alternative measure of operating performance to net income (determined in accordance with GAAP) since it does not reflect the aforementioned excluded items. Further, NOI may not be comparable to that of other REITs, as they may use different methodologies for calculating NOI.

The following table reconciles NOI from net income (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,			
		2012	2011		2012		2011	
Net income	\$	199,043	\$	175,471	\$	600,582	\$	483,707
Interest income		(10,278)		(577)		(12,313)		(99,199)
Investment management fee income		(460)		(494)		(1,423)		(1,605)
Interest expense		103,513		103,459		309,875		315,695
Depreciation and amortization		88,686		86,672		259,039		265,742
General and administrative		19,443		19,647		54,356		76,471
Impairments		7,878		15,400		7,878		15,400
Other income, net		(770)		772		(2,233)		(17,056)
Income taxes		(598)		5		(1,131)		289
Equity income from unconsolidated joint ventures		(13,396)		(17,050)		(42,803)		(32,798)
Total discontinued operations, net of taxes		(984)		(809)		(2,440)		(3,796)
NOI	\$	392,077	\$	382,496	\$	1,169,387	\$	1,002,850
Straight-line rents		(11,821)		(14,024)		(33,608)		(46,936)
DFL accretion		(23,433)		(23,571)		(71,072)		(48,508)
Amortization of above and below market lease intangibles, net		(533)		(1,178)		(1,855)		(3,271)
Lease termination fees		(175)		(239)		(574)		(3,417)
NOI adjustments related to discontinued operations		335		516		1,437		1,585
Adjusted NOI	\$	356,450	\$	344,000	\$	1,063,715	\$	902,303

Occupancy. For life science facilities and medical office buildings, occupancy represents the percentage of total rentable square feet leased where rental payments have commenced, including month-to-month leases, as of the end of the period reported. For senior housing facilities, post-acute/skilled nursing facilities and hospitals, occupancy represents the facilities' average operating occupancy for the trailing three-month and 12-month periods and one quarter in arrears from the date reported. The percentages are calculated based on units, licensed beds and available beds for senior housing facilities, post-acute/skilled nursing facilities and hospitals, respectively. The percentages shown exclude newly completed facilities under lease-up, vacant facilities and facilities for which data is not available or meaningful. All facility financial performance data was derived solely from information provided by operators/tenants and borrowers without independent verification by the Company. For the SPP, occupancy for senior housing facilities, post-acute/skilled nursing facilities and hospitals are presented based on the average operating occupancy for the trailing three-month and 12-month periods and one quarter in arrears from the date reported.

Owned Portfolio. Represents owned properties subject to operating leases and DFLs, properties operated under a RIDEA structure and debt investments, and excludes properties under development, including redevelopment, land held for development and real estate owned by the Company's unconsolidated joint ventures.



**Pooled Leases.** Two or more leases to the same operator/tenant or their subsidiaries under which their obligations are combined by virtue of a master lease or multiple master leases, a pooling agreement or multiple pooling agreements, or cross-guaranties. For example, Sunrise Senior Living percentage pooled consists of 47 assets under 6 separate pools.

Quality Mix. Represents non-Medicaid revenues as a percent of total revenues for the trailing 12 months and is one quarter in arrears from the period presented.

Redevelopment Projects. Properties that require significant capital expenditures (generally more than 25% of acquisition cost or existing basis) to achieve stabilization or to change the use of the properties.

**Rehabilitation Hospitals ("Rehab").** Rehabilitation hospitals provide inpatient and outpatient care for patients who have sustained traumatic injuries or illnesses, such as spinal cord injuries, strokes, head injuries, orthopedic problems, work-related disabilities and neurological diseases.

Rental and RIDEA Revenues. Represents rental and related revenues, tenant recoveries, resident fees and services, and income from direct financing leases.

Retention Rate. Represents the ratio of total renewed square feet to the total square feet expiring and available for lease, excluding the square feet for tenant leases terminated for default or buy-out prior to the expiration of their lease.

RIDEA. The Housing and Economic Recovery Act of 2008 (commonly referred to as "RIDEA").

Same Period Rent. The base rent plus additional rent due to the Company over the trailing 12 months and one quarter in arrears from the date reported. The Company uses Same Period Rent for purposes of determining property-level Cash Flow Coverage.

Same Property Portfolio ("SPP"). SPP statistics allow management to evaluate the performance of the Company's real estate portfolio under a consistent population, which eliminates the changes in the composition of the Company's portfolio of properties. The Company identifies its SPP as stabilized properties that remained in operations and were consistently reported as leased properties or operating properties (RIDEA) for the duration of the year-over-year comparison periods presented. Accordingly, it takes a stabilized property a minimum of 12 months in operations under a consistent reporting structure to be included in the Company's SPP. SPP NOI excludes certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.

Secured Debt Ratio. Total Secured Debt divided by Total Gross Assets. The Company believes that its Secured Debt Ratio is a meaningful supplemental measure of its financial position, which enables both management and investors to analyze its leverage and to compare its leverage to that of other companies. The Company believes that the ratio of Consolidated Secured Debt to Consolidated Gross Assets is the most directly comparable GAAP measure to Secured Debt Ratio. The Company's computation of its Secured Debt Ratio may not be identical to the computations of Secured Debt Ratio reported by other companies. The Company's pro rata share of total secured debt from the Investment Management Platform is not intended to reflect its actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the joint ventures. The Company has provided reconciliations of this measure to the most comparable GAAP measure in this supplemental information package and for certain historical trend information on page 6, such reconciliations are available in the Company's Current Reports on Form 8-K filed with the SEC dated February 14, 2012 (2011 metrics), February 15, 2011 (2010 metrics), February 12, 2010 (2009 metrics), February 10, 2009 (2008 metrics), February 11, 2008 (2008 and 2007 metrics) and July 30, 2007 (Pre-CNL Acquisition metrics).

Senior Housing. ALFs, ILFs and CCRCs.

Specialty Hospitals. Specialty hospitals are licensed as acute care hospitals but focus on providing care in specific areas such as cardiac, orthopedic and women's conditions, or specific procedures such as surgery, and are less likely to provide emergency services.

Square Feet. The square footage for properties, excluding square footage for development or redevelopment properties prior to completion.

**Stabilized.** Newly acquired operating assets are generally considered stabilized at the earlier of lease up (typically when the tenant(s) controls the physical use of 80% of the space) or 12 months from the acquisition date. Newly completed developments, including redevelopments, are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service.

Total Debt. Consolidated Debt at book value plus the Company's pro rata share of total debt from the Investment Management Platform.

Total Gross Assets. Consolidated Gross Assets plus the Company's pro rata share of total assets from the Investment Management Platform, after adding back accumulated depreciation and amortization.

The following table details the calculation of Total Gross Assets (in thousands):

		2012	 2011	2011		
Consolidated total assets	\$	18,079,336	\$ 17,408,475	\$	17,439,377	
Investments in and advances to unconsolidated joint ventures		(217,092)	(224,052)		(225,979)	
Accumulated depreciation and amortization		1,887,380	1,651,835		1,623,391	
Accumulated depreciation and amortization from assets held for sale		27,930	22,371		27,294	
Consolidated gross assets	\$	19,777,554	\$ 18,858,629	\$	18,864,083	
HCP's share of unconsolidated total assets <sup>(1)</sup>		266,928	269,606		276,277	
HCP's share of unconsolidated accumulated depreciation and amortization <sup>(1)</sup>		45,044	40,104		38,636	
Total gross assets	\$	20,089,526	\$ 19,168,339	\$	19,178,996	

<sup>(1)</sup> Reflects the Company's pro rata share of amounts from the Investment Management Platform and its equity interest in HCR ManorCare OpCo.



Total Market Capitalization. Total Debt plus Total Market Equity.

**Total Market Equity.** The total number of outstanding shares of the Company's common stock multiplied by the closing price per share of its common stock on the New York Stock Exchange as of period end, plus the total number of convertible partnership units multiplied by the closing price per share of its common stock on the New York Stock Exchange as of period end (adjusted for stock splits), plus the total number of outstanding shares of the Company's preferred stock multiplied by the closing price of its preferred stock on the New York Stock Exchange as of period end.

Total Secured Debt. Consolidated Secured Debt plus the Company's pro rata share of mortgage debt from the Investment Management Platform.

Units/Square Feet/Beds. Senior housing facilities are measured in units (e.g., studio, one or two bedroom units). Life science facilities and medical office buildings are measured in square feet. Post-acute/skilled nursing facilities and hospitals are measured in licensed bed count.

Yield. Yield is calculated as Net Operating Income, as adjusted, divided by Investment. For acquisitions, initial yields are calculated as projected Net Operating Income, 12 months forward, as adjusted, as of the closing date divided by total acquisition cost basis. The total acquisition cost basis includes the initial purchase price, the effects of adjusting assumed debt to market, lease intangible adjustments and all transaction costs.

